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Abbreviations used 
 
2-AG – 2- Arachidonoylglycerol 
ABHD6 – α/β-Hydrolase domain containing 6 
ABHD12 – α/β-Hydrolase domain containing 12 
APS – Ammonium persulfate 
BIS - N,N'-methylen-bis-acrilamide 
BL - Bioluminescence 
BSA – Bovine serum albumine 
cAMP – cyclic adenosine monophospate 
CB – Cannabinoid receptor 
CL - Chemiluminescence 
CHRM4 - Muscarinic acetylcholine receptor M4 
CNS – Central nervous system 
DCC – N,N'-Dicyclohexylcarbodiimide 
DEA - Docosatetraenylethanol amide 
DMAP - 4-Dimethylaminopyridine 
DTT – Dithiothreithol ((2S,3S)-1,4-Bis(sulfanyl)butane-2,3-diol) 
ERK – Extracellular signal-regulated kinase 
EC – Endocannabinoid 
ES – Endocannabinoid system 
FAAH – Fatty acid amide hydrolase 
FABP – Fatty acid binding protein 
GPCR – G-protein coupled receptor 
GPR119 - G-protein coupled receptor 119 
IPTG - Isopropyl β-D-1-thiogalactopyranoside 
IMAC – Immobilized metal affinity chromatography 
LB – Lysogeny broth (Bertani, 2004) 
LH2 – D-luciferin 
MAD – Multiple ascending dose 
MAGL – Monoacylglycerol lipase 
MAPK – Mitogen-activated protein kinase 
NADA - N-arachidonoyl dopamine 
NAPE - N-arachidonoylphosphatidylethanolamine 
NAPE-PLD - N-acylphosphatidylethanolamine-hydrolyzing phospholipase D 
NAT – N-acyltransferase 
OD – Optical density 
OEA - Oleoylethanolamide 
o/n – overnight (a time period of about 14 hours) 
PBS – Phosphate buffer saline 
PCB – Protease cleavage buffer 
PE- Phosphatidilethanolamine 
PEA - Palmitoylethanolamide 
PHARC - polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract 
PKA – cAMP-dependent protein kinase 
PMSF - phenylmethylsulfonyl fluoride 
PPAR-α – Peroxisome proliferator-activated receptor 
PTX – Pertussis toxin 
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RFU – Relative fluorescence units 
RLU - Relative luminescence units 
RT – Room temperature 
SD – Standard deviation 
SDS - Sodium dodecyl sulfate 
SDS-PAGE – Sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
TBS – Tris-buffered saline 
TGS – Tris, glycine, SDS 
TE – Tris and EDTA  
TEMED – Tetramethylenediamine 
THC - (−)-trans-Δ⁹-tetrahydrocannabinol 
TLC – Thin layer chromatography 
TRPV1 - transient receptor potential cation channel subfamily V member 1 
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1.1 The hidden system 
“System” is a word that evokes unmistakable concepts: didactic schemes of the respiratory, 
circulatory and nervous systems, all come to the mind when a non-specialist (and possibly 
even a specialist) thinks about a “system” of the human body. 
The endocannabinoid system (ES), however, is not so easy to describe: it actually has no 
organs, tissues, nor even cells of its own: its only constituents are molecules. The whole 
system is “embedded” into other, “proper” systems: its components can be found at the 
surface of immune cells, as well as at the neuronal synapses, and across a lot of other different 
systems, throughout the whole body. On top of this, it does not even have a function of its 
own: it just modulates the activities of other, “truer” systems. The picture, then, may look 
quite discomforting: the system we’re considering has no organs, no specific anatomical 
location, nor function, of its own. Actually, the very definition of “system” is debatable, when 
referring to the ES. All it does is to enhance or reduce the effects of other, “truer” systems, 
from imprecise localizations in the body. 
And yet, after a deeper insight into it, it immediately becomes evident that its peculiarities, 
which at first make it look obscure at best, are also what makes the ES so special and 
interesting. The lack of a precise anatomical district of its own, so that it can be brilliantly 
described as being “here, there, and everywhere” (Vettor, Pagotto, Pagano, & Pasquali, 2008), 
allows the ES to exert its functions on a huge variety of tissues and body districts, which 
greatly differ from one another. The other peculiarity of the ES, that of not having a specific 
function of its own, further enhances this versatility: since it does nothing but modulate an 
array of activities coming from other, specialised systems, its activity is exerted on a lot of 
different functions. These can be briefly, and incompletely, summed up as: 
Target organ or system ES localisation and function 
Nervous system Synapses and glial cells; pain control (Woodhams, Chapman, Finn, 
Hohmann, & Neugebauer, 2017), feeding behavior (Shrestha et al., 
2018), regulation of stress and reward mechanism, sense of general well-
being (Volkow, Hampson, & Baler, 2017), thermal homeostatis (Nass et 
al., 2015). 
Immune system Surface of lymphocytes; immunomodulatory activity, inhibition of 
inflammatory reaction (Cabral, Rogers, & Lichtman, 2015). 
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Bone system Osteoblasts, chondrocytes, nerve terminals; promotion of bone formation 
and repression of bone resorption, regulation of bone growth during 
development (Zimmer, 2016). 
White fat Adipocytes; modulation of energy expenditure (Shrestha et al., 2018) 
 
An insight on the structure of the ES will help understand how the ES can perform such 
diverse functions. 
1.1.1 Endocannabinoid receptors 
The molecular components of the ES can be broadly sub-classified into three classes of 
molecules: receptors (CBs), endocannabinoids (ECs) and regulating enzymes. 
To date, we know two kinds of endocannabinoid receptors, namely cannabinoid receptor 1 
(CB1), and cannabinoid receptor 2 (CB2). The identity number of these receptors refers to the 
timing of their discovery: CB1 was the first CB to be discovered and characterized from rat 
brain (W. A. Devane, Dysarz, Johnson, Melvin, & Howlett, 1988; Matsuda, Lolait, 
Brownstein, Young, & Bonner, 1990), while CB2 was identified three years later in rat spleen 
and in a variety of other tissues, but not in the brain (Munro, Thomas, & Abu-Shaar, 1993). 
Both CB1 and CB2 are heteroreceptors which share the typical structure of GPCRs: they both 
are made up of seven transmembrane domains, connected by three extracellular and three 
intracellular loops, with a glycosylated N-terminus and an intracellular C-terminus (Hua et al., 
2016; Shao et al., 2016). The specific mechanism of action varies among cell types; in most 
cases, though, once the CBs are activated by interaction with their ligands (Table 1), the Gαi 
subunit coupled to them inhibits adenylyl cyclase, thus lowering the intracellular 
concentration of adenosine monophosphate (cAMP). cAMP activates cAMP-dependent 
protein kinases (PKAs), which have many different roles in the cell through many different 
mechanisms – these vary greatly depending on the cell type (R. G. Pertwee, 2006; R G 
Pertwee et al., 2010). A review of these mechanisms lies far beyond the aims of this 
dissertation, but we can (very briefly) summarize the roles of PKAs as having an “activating” 
role in the cell; the CBs, being indirect inhibitors of their activity, can be therefore roughly 
considered “dampeners” of the activity of the cell. CBs also raise the cellular levels of 
mitogen-activated protein kinases (MAPKs), also known as “Extracellular signal-regulated 
kinases” (ERKs). These kinases, in turn, continue the cascade response, activating an 
extremely different varied array of responses, including expression of genes and cell 
differentiation, proliferation and death. Again, a complete review of different MAPK 
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activation and response should be the subject of a dissertation of its own, but in the context of 
the ES these processes can be roughly summarized as “stress responses”, both at cellular and 
physiological level (Morena, Patel, Bains, & Hill, 2016; Volkow et al., 2017). 
CB1 can be found mainly across the central nervous system (CNS), where the ES acts as a 
neuromodulator. Here, the ES activity can have a twofold output in terms of physiological 
response: in the case of excitatory (e.g. glutamatergic) neurons, its activity results in a 
decreased rate of neural activity; but should the ES activate at the synapse between two 
GABAergic (inhibitory) neurons, the result would be an increase in physiological neural 
transmission. CB1-mediated response may act as an endogenous mechanism of pain control 
through the elevation of ECs levels in the regions of acute and chronic pain, acting as 
“endogenous analgesics” (Woodhams et al., 2017). CB1s can also have an important role in 
human metabolism and feeding behavior (Shrestha et al., 2018): they are expressed in various 
tissues including fat, muscle and liver cells, as well as throughout the digestive tract. These 
receptors can also be found across a variety of glands within the endocrine system, including 
the pituitary, thyroid and adrenal gland, and within the reproductive system in both sexes 
(Pagotto, Marsicano, Cota, Lutz, & Pasquali, 2006). The most recent breakthrough in the 
study of  CB1, though, has been the resolution of its crystal structure (fig.1) (Hua et al., 2016; 
Shao et al., 2016), opening the perspective of structure-based drug design for this receptor. 
The main endogenous agonist for CB1 is 2-arachidonoylglycerol (2-AG), with a Ki of 58.3 
Figure 1. Crystal structure of CB1 receptor in complex with the inhibitor AM6538, transmembrane (A) and top (B) view. The 
position of AM6538 marks the location of the binding pocket, partially blocked by the N-ter loop (right, in red). Also marked are 
the extracellular and intracellular loops (ECL and ICL, respectively) and ECL2 disulfide bond. The Roman numerals label the 
various helix numbers. Image taken from Hua et al., 2016. 
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nM (R G Pertwee et al., 2010); the famous phytocannabinoid (−)-trans-Δ⁹-
tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis sativa1, is a 
partial agonist of both CB1 and CB2 receptors, though its affinity for the receptor is about ten 
times that of 2-AG. It is activated also by noladin ether, with a Ki of 21.2 ± 0.5 nM (L. Hanuš 
et al., 2001) – for a complete perspective on CB ligands, refer to Table 1.  
A complete crystal structure for CB2 is not available yet,  but various in-silico surrogates have 
been published (Cichero, Menozzi, Guariento, & Fossa, 2015; Tuccinardi et al., 2006). The 
precise distribution of CB2 across the human body is still uncertain: earlier studies described 
CB2 as a “peripheral” endocannabinoid receptor and excluded its presence in the brain 
(Munro et al., 1993), but later immunohistochemical studies found it was localised in the mice 
brain as well (Onaivi et al., 2006). Problem was, the same antibodies shown analogous results 
when used on CB2-knockdown mice (Baek, Darlington, Smith, & Ashton, 2013), and it was 
later demonstrated that these antibodies were sensitive but not specific (Cecyre, Thomas, 
Ptito, Casanova, & Bouchard, 2014). To add further uncertainty, some studies connect the 
effect of dopamine on CB2 receptors to drug addiction behaviour in mice and rats (Xi et al., 
2011; Zhang et al., 2014, 2017) which seems to indicate their presence in the brain. CB2 even 
mediate antipsychotic effects of drugs acting on muscarinic receptor CHRM4 in mice models 
(Foster et al., 2016). Today we still don’t know with certainty if CB2 is a purely peripheral 
receptor, but recently developed tools for its investigation, including antagonists for CB2 
which are extremely specific, and mice which express GFP if CB2 is expressed as well 
(Rogers, 2015), will maybe allow us to finally understand its true tissue distribution. What we 
know for sure, though, is that CB2s are present within cells of the immune system, where they 
play an important role in modulating the immune response (Cabral & Griffin-Thomas, 2009). 
The general view on what the CBs exactly are is not so defined, however. Different receptors 
are, or have been in time, indicated as a “CB3” receptor. 
The transient receptor potential cation channel subfamily V member 1 (vanilloid receptor 1, 
capsaicin receptor, TRPV1), strongly implied in nociception and, potentially, pain therapy 
(Knotkova, Pappagallo, & Szallasi, 2008) is activated by monoacylglycerols including 2-AG 
and anandamide, to the point that anandamide is suggested to be an endovanilloid as well 
(Zygmunt et al., 2013) and, paradoxycally, may enhance the pain sensation. On the other side, 
                                                
1 It is actually debated if Cannabis indica and C. ruderalis, all of which biosynthesize THC, are species of their own or 
instead subspecies of the C. sativa species; we will embrace this last view and leave the debate to specialists in plant 
taxonomy. 
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N-arachidonoyl dopamine (NADA), the endogenous ligand for TRPV1 (Bisogno et al., 2000), 
is an agonist of CB1 and CB2 as well, even if with limited potency (Huang et al., 2002). 
TRPV1 is not considered a constituent of the ES, but all these findings indicate that the ES 
and the pain mechanism mediated by TRPV1 share more than one mechanism of action. 
The Peroxisome-proliferator activated receptor α (PPAR-α), a transcription factor and 
regulator of lipid metabolism found in the liver, can be activated by anandamide, virodhamine 
and noladin ether, showing that the importance of ECs in lipid metabolism is multi-faceted, 
and the levels of these molecules can have an impact in unforeseen ways. AEA can also 
activate PPAR-γ, another member of the family (O’Sullivan, 2007). 
A few G-protein coupled receptors (GPRs) have been in time identified as novel CB 
receptors: GPR18 has a role in immune regulation, is activated by the AEA metabolyte N-
arachidonoylglycine (Kohno et al., 2006), even if not in a canonical way (Lu, Puhl, & Ikeda, 
2013). GPR55 is activated by 2-AG, anandamide, and noladin ether as well as THC, so was 
classified as a novel cannabinoid receptor (Ryberg et al., 2007). However, later studies found 
that the activity mediated by endogenous N- ethanolamides was moderate at best (Godlewski, 
Offertáler, Wagner, & Kunos, 2009). GPR55 also binds Lysophospatidylinositol (LPI) (Oka, 
Nakajima, Yamashita, Kishimoto, & Sugiura, 2007), definitely seems to be its main 
endogenous ligand (Piñeiro & Falasca, 2012). GPR55 has various analogies with “proper” 
CBs, since its action is mediated by lipid signaling and has an important role in metabolic 
disease (Arifin & Falasca, 2016) as well as pain perception (Godlewski et al., 2009). The final 
candidate, GPR119, acts following oleoylethanolamide binding (Overton et al., 2006) and 
seems to have a role in the regulation of food intake behaviour (Godlewski et al., 2009). 
To date, no “true” CB3 has yet been definitely identified. There are some clear interactions 
beetween the ES and other lipid signaling pathways, to the point that it is entirely possible 
that in the future no “endocannabinoid system” will be considered, but it will rather be 
included in “a wider lipid-based signaling system” (Di Marzo & De Petrocellis, 2012).  
The puzzle has yet to be solved. 
1.1.2 Endocannabinoids 
The discovery of cannabinoid receptors subsequently led to the research of endogenous 
ligands: in 1992, a group led by professor Raphael Mechoulam, the same researcher who in 
1964 discovered THC (Gaoni & Mechoulam, 1964), isolated and then synthesized an 
endogenous arachidonic acid derivative from porcine brain, which demonstrated to be able to 
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bind CB1: this compound was named Anandamide (Arachidonoyl ethanolamide, AEA), “from 
the sanskrit word “Ananda” meaning bliss, and from the chemical nature of the compound” 
(W. Devane et al., 1992). It was later retrieved in human brain, thus confirming its role as an 
endocannabinoid (Felder et al., 1996). 
However, anandamide was present in very low levels among brain tissues (Felder et al., 
1996), and it acted only as a partial agonist for both CB1 and CB2  (Mackie, Devane, & Hille, 
1993). A few years later, another compound binding the cannabinoid receptors originally 
discovered in canine intestines (Mechoulam et al., 1995) was found in human brain: this 
compound was 2-arachidonoylglycerol (2-AG), which is present in the human brain in about 
170 times the concentration of anandamide (Stella, Schweitzer, & Piomelli, 1997).  
The generally accepted mechanism fo AEA biosynthesis starts from membrane 
phospholipids, to have them into converted AEA through a 2-steps n-acylation of 
phosphatidilethanolamine (PE). Ca2+-dependent N-acyltransferase (NAT) catalyzes the first 
step, the acylation of the amino group of PE with an arachidonoyl coming from a 
glycerophospholipid, leading to the formation of N-arachidonoylphosphatidylethanolamine 
(NAPE). NAPE is then hydrolized to a phosphatidic acid and AEA by the enzyme N-
acylphosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD) (J. Wang & Ueda, 
2009). It is interesting to note that the activity of NAPE-PLD is regulated by bile acids, 
suggesting that this enzyme could play a central role in the orchestration between ES 
signaling regulation and food intake (Magotti et al., 2015). 
2-AG binds CB1 receptors with more or less the same affinity of AEA, and CB2 with about 
twice the affinity (Table 1); more important, 2-AG is a full agonist of both receptors, unlike 
anandamide, which even attenuates 2-AG activity (Gonsiorek et al., 2000). It is considered 
the main signaling lipid in the ES. 
Table 1. Agonists of the cannabinoid receptors. FA= full agonist; PA=partial agonist 
Endogenous ligands 
Compound Structure Ki for CB1 Ki for CB2 Reference Notes 
2-Arachidonoyl glycerol (2-AG) 
 
58.3 nM 145 nM (R G Pertwee et al., 2010) FA 
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Anandamide (AEA) 
 
61 nM 279 nM (R G Pertwee et al., 2010) PA 
N-arachidonoyl dopamine 
(NADA) 
 
250 nM 12 µM (Bisogno et al., 2000) 
EC50 for 
TRPV1: 40 ± 
6 nM (Huang 
et al., 2002) 
2-Arachidonyl glyceryl ether (2-
AGE, Noladin ether)  
21.2 ± 0.5 nM 480 nM (Shoemaker, 2005) FA 
Docosatetraenylethanolamide 
(DEA) 
 
34.4 ± 3.2 nM  
(on synaptosomal rat membrane) 
(Lumir Hanuš, Gopher, Almog, & 
Mechoulam, 1993) 
 
Homo-γ-linolenylethanolamide 
 
53.4 ± 5.5 nM  
(on synaptosomal rat membrane) 
 
Virodhamine 
 
912 ± 99 nM 
No available 
data 
(Steffens, Zentner, Honegger, & 
Feuerstein, 2005) 
 
Exogenous ligand (phytocannabinoid) 
Compound Structure Ki for CB1 Ki for CB2 Reference Notes 
(−)-trans-Δ⁹-tetrahydrocannabinol 
(THC) 
 
5.05 ± 0.65 nM 3.13 ± 0.34 nM 
(Iwamura, Suzuki, Ueda, 
Kaya, & Inaba, 2001) 
PA; this is the most 
recent of many reported 
different values - 
Pertwee, 2008 
The biosynthesis of 2-AG starts from inositol phospolipids containing arachidonic acid: a 
phospholipase–C hydrolyzes phosphatidylinositol-4,5- bisphosphate (PIP2) to inositol 1,4,5-
trisphosphate and diacylglycerol (DAG). The DAG is subsequently hydrolyzed at sn-1 
position into a free fatty acid and a monoacylglycerol, 2-AG by one of two diacylglycerol 
lipases (DAGL) – DAGLα and DAGLβ (Murataeva, Straiker, & Mackie, 2014; J. Wang & 
Ueda, 2009). Two alternate pathways for the biosynthesis of 2-AG are the dephosphorylation 
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of arachidonoyl-lysophosphatidylinositol and the sequential action of PLA1 and a 
lysophospholipase C (lyso-PLC) (Murataeva et al., 2014). 
Other putative endocannabinoids have then been discovered, from amides like Homo-γ-
linolenylethanolamide, Docosatetraenylethanol amide (DEA) (Lumir Hanuš et al., 1993), N-
arachidonoyl dopamine (NADA) (Huang et al., 2002) and the ether compounds Noladin ether, 
which binds to CB1 but very weakly to CB2 (L. Hanuš et al., 2001), and Virodhamine, for 
which we have only data regarding CB1 (Steffens et al., 2005). 
Other ethanolamides classified as “putative endocannabinoids” have been found in tissues, 
like Palmitoylethanolamide (PEA) and Oleoylethanolamide (OEA); these saturated or 
monoinsaturated amides do not bind directly the CBs, but rather the PPAR-α, GPR119 and 
the TRPV-1 receptors (Godlewski et al., 2009; Keppel Hesselink, De Boer, & Witkamp, 
2013; Laleh et al., 2018; Petrosino, Iuvone, & Di Marzo, 2010). OEA and PEA have also 
been found to potentiate anandamide effect (the so-called “entourage effect”) in non-vascular 
tissues in rats, through the activation of TRPV1 (Ho, Barrett, & Randall, 2008; Petrosino et 
al., 2010), thus further suggesting that AEA/ethanolamides stand at the crossing between 
different lipid signaling pathways. 
Endocannabinoids signaling at the synaptic cleft 
Synaptic depolarization or activation of Gq/11-coupled GPCRs (such as glutamate receptors) 
trigger the activation of the PLC in the postsynaptic neuron. The hydrolysis of membrane 
PIP2 yields a DAG which, in turn, is the substrate of DAGL. The newly synthesized 2-AG is 
hydrophobis enough to cross the cell membrane without transporters of sort, and is released 
into the synaptic cleft. Here, it reaches the presynaptic neuron through a process which has 
not been fully identified yet, probably through a transporter of some sort, where it reaches the 
CB1 of the presynaptic neuron. Upon ligand binding and receptor activation, CB1 receptors 
are primarily coupled to pertussis toxin (PTX)- sensitive Gi/o type G proteins which lead to a 
rapid decrease in levels of cAMP by inhibiting adenylate cyclase activity. The decrease in 
cAMP levels, in turn, inhibit Ca2+ metabotropic channels; the G protein activity inhibits also 
voltage-gated Ca2+ channels and K+ channels, avoiding hyperpolarisation. The closing of Ca2+ 
prevents the release of more neutransmitter in the synaptic cleft, completing the general 
inhibitory action of CB1, the so-called endocannabinoid-generated short-term depression 
(Kendall & Yudowski, 2017; Ohno-Shosaku & Kano, 2014). The CB1 receptor will then enter 
2-AG into the cell, where it will be inactivated by monoacylglycerol lipase (fig. 2). 
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Mechanisms of action for AEA have not been fully elucidated yet; it is thought to participate 
both in a retrograde signaling pathway, resembling the action of 2-AG, and an intracellular 
one, acting onto the postsynaptic neuron TRPV1 receptors, thus lowering the Ca2+ levels of 
this cell to induce postsynaptic depression. Since it is degraded inside the cell, at the 
endoplasmic reticulum, its main role seems that of intracellular signaling (Deutsch, 2016; 
Ohno-Shosaku & Kano, 2014).  
 
Figure 2. Endocannabinoid system signaling at the synaptic cleft. Image from Di Marzo, Bifulco & De Petrocellis, 2004. 
1.1.3 Regulatory enzymes 
Once ECs have exerted their function on CBs, their signaling function must be shut down in 
order to be regulated. This is achieved through their hydrolysis to the corresponding fatty acid 
and the conjugated alcohol or amine: this function is controlled by the hydrolytic regulatory 
enzymes of the ES. 
These hydrolases are fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) 
and α/β-Hydrolase domain (ABHD)-containing protein 6 and 12 (ABHD6 and ABHD12). All 
of them are serine hydrolases and integral membrane proteins or, in the case of MAGL, 
membrane-bound enzymes (Blankman, Simon, & Cravatt, 2007; Labar et al., 2010; Mileni et 
al., 2010), which seems to fit their role of fine tuning the ECs levels right after their action on 
CBs (J. R. Savinainen, Saario, & Laitinen, 2012). 
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FATTY ACID AMIDE HYDROLASE (FAAH) 
FAAH was the first regulating enzyme to be discovered (Dale G. Deutsch & Chin, 1993). It is 
a member of the amidase signature family, which can hydrolyze in vitro both amides and 
esters, as well as other N-acilethanolamines (fig. 3) (Cravatt et al., 2001). At physiological 
level, however, the pharmacological blockade of FAAH in rats has demonstrated to greatly 
raise the levels of AEA, but not those of 2-AG (Kathuria et al., 2003) and to contribute to the 
hydrolysis of ~1% of brain 2-AG (Blankman et al., 2007). Actually, in 2006 it was discovered 
that two FAAH proteins are encoded in humans and higher mammals, FAAH-1 and FAAH-2: 
FAAH-2 showed to hydrolyze preferentially OEA, while FAAH-1 has a substrate preference 
for AEA (Wei, Mikkelsen, McKinney, Lander, & Cravatt, 2006), thus suggesting the crossing 
between different lipid signaling systems. FAAH has a unique cellular location, at the 
endoplasmic reticulum: AEA is brought here by a putative transporter, known as Fatty Acid 
Binding Protein (FABP) (Deutsch, 2016). 
 
Figure 3. General reaction scheme for hydrolysis catalyzed by MAGL and ABHD esterases (top) and FAAH amidase 
(bottom). 
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MONOACYLGLYCEROL LIPASE (MAGL) 
 
MAGL is the main responsible for the regulation of 2-AG at CB1 neuronal sites (Dinh et al., 
2002), accounting for about 85% of its hydrolysis (Saario et al., 2005), although capable of 
hydrolyzing many different 1-AG molecules (fig. 3) (Navia-Paldanius, Savinainen, & 
Laitinen, 2012). MAGL structure is summarized in fig. 4: it is a 33 Kda protein, anchored to 
the membrane through the hydrophobic A4 helix, situated next to the lid domain where the 
substrate is recruited (Bertrand et al., 2010; Labar et al., 2010). This peculiar structural feature 
also accounts for the proposed catalytic cycle of MAGL, consisting in the recruitment of the 
substrate from the membrane, which is then hydrolyzed and released in the cytoplasm 
folowing a membrane detachment of the enzyme; MAGL then binds the membrane again via 
the A4 helix, and the cycle can begin anew. The catalytic cycle is made possible by the 
plasticity of the lid domain, and this substrate recruitment mechanism could account for its 
substrate specificity in the cell (Riccardi et al., 2017). MAGL structure also has some peculiar 
features: once the substrate is recruited in its lid domain, it enters the enzyme through a 
hydrophobic channel which leads to the catalytic site. Here, the substrate is accommodated so 
that the ester oxygen faces the serine of the catalytic triad, composed by Ser122, His 269 and 
Asp239 (Karlsson, Contreras, Hellman, Tornqvist, & Holm, 1997). The ester is hydrolyzed 
via a classic serine hydrolase mechanism, then the glycerol leaving group is thought to exit 
the protein core through a side exit channel, leading into the cytoplasm (Labar et al., 2010). It 
is interesting to note that the synaptic localization of these two enzymes is different in rats, 
with FAAH being found mainly in postsynaptic regions, and MAGL in presynaptic ones: this 
Figure 4. MAGL structure, with the catalytic triad 
(blue), leaving group exit channel (orange), 
hydrophobic (yellow) and hydrophilic (green) 
binding pockets highlighted. The enzyme is 
depicted here with the A4 membrane binding helix 
on the right. The “gate” phenylalanine residues 93 
and 209 (purple) are a putative “gate” which is 
thought to control substrate access to the catalytic 
site during conformational changes. Cys208 and 
Cys 242 are thought, along with Cys201, to 
stabilize MAGL conformation and interact with 
some substrates, such as maleimides. Moreover, 
these three cysteines have been proposed to control 
MAGL inhibition through an oxidation-dependent 
mechanism (Scalvini et al., 2016).  
Image from Tuo et al., 2017. 
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seems to follow the main role of 2-AG as a retrograde signaling molecule, and the one of 
AEA as being primarily an intracellular messenger (Gulyas et al., 2004). 
Α/Β DOMAIN-CONTAINING HYDROLASE 6 AND 12 (ABHD6 AND ABHD12) 
In the central nervous system, the remaining 2-AG is hydrolyzed by two other lipases: 
ABHD6 (~4%) and ABHD12 (~9%) (fig.3), while the remaining ~1% is hydrolyzed by 
FAAH (Blankman et al., 2007). Both ABHD6 and ABHD12 are predicted to be integral 
membrane proteins: ABHD6 is a ~36 Kda protein, thought to have its active site facing the 
interior of the cell, while ABHD12 (a ~45KDa glycoprotein) should face the outward of the 
cell. In addition to MAGL hanging on the cytosolic side of the membrane, these three 
enzymes were thought to control the action of 2-AG in neurons (Blankman et al., 2007; Marrs 
et al., 2010; Navia-Paldanius et al., 2012) and microglia where, in cells which lack the 
expression of MAGL, ABHD6 grants the control of levels of 2-AG (Marrs et al., 2010; 
Muccioli et al., 2007). More recently, however, they both have been found to have an in vitro 
substrate preference for 1(3)-acylglycerols of unsaturated fatty acids (Navia-Paldanius et al., 
2012); in vivo, ABHD12 hydrolyzes lysophosphatidylserine (LPS) in mammalian brain, and 
has been straightforwardly linked to the neurodegenerative disease which involves 
polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC), (Blankman, 
Long, Trauger, Siuzdak, & Cravatt, 2013; Fiskerstrand et al., 2010). While still not much is 
known about these hydrolases, there indeed are some tools useful for their study: the 
carbamate inhibitor WWL70 was found to have specificity for ABHD6 (W. Li, Blankman, & 
Cravatt, 2007). Also, specific inhibitors for ABHD12 in the form of triterpenoids have 
recently been developed (Parkkari et al., 2014). 
 
1.1.4 Therapeutical interest 
The ES has been of therapeutical interest at least since the days of Ancient Egypt, around 
1700 B.C. - but more uncertain references could date its medicinal use back to 2350 B.C. 
(Russo, 2007). The Papyrus Ramesseum III reports a preparation of ground celery and hemp, 
which had to be used to wash the eyes of the patient – a possible reference to glaucoma, one 
of the most common conditions for which cannabis is still used (Novack, 2016).  
Due to the fact that the ES exerts its modulating activity on a variety of systems, its 
therapeutic potential is vast, and is being investigated since the early days of its discovery. 
The first approach was that of directly targeting the CBs, with both agonists (THC-like): aside 
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from and THC and cannabis-derived molecules, the first approved drug in Europe for 
treatment of obesity through the inhibition of CB1 was Rimonabant, in 2006. Rimonabant is 
an inverse agonist for the selective blockade of CB1, and gave hopes for an effective 
treatment of multiple metabolic risk factors, including smoking cessation (Gelfand & Cannon, 
2006). While effective, in 2009, however, Rimonabant was retired from the EU market due to 
its severe psychological side effects: about 11.5% of the patients suffered from depression and 
anxiety, and a few planned suicide (Moreira & Crippa, 2009; Sam, Salem, & Ghatei, 2011). 
This taught that drugs targeting the ES have to be tuned very finely, since the vast extent of its 
activities can bring unpredictable consequences. 
The inhibition of regulatory enzymes, thus enhancing the levels of endocannabinoids, has 
been a promising way for the development of new drugs targeting the ES as well (Toczek & 
Malinowska, 2018; Tuo et al., 2017). FAAH, the first regulating enzyme to be discovered and 
the best characterized one, has recently been the target of a clinical trial in the hope that 
FAAH blockade would have been able to treat pain, anxiety and inflammatory states. The 
blockade of FAAH was achieved through the irreversible inhibitor BIA 10-2474. After only 5 
days from the start of a multiple-ascending dose (MAD) phase which was planned to last for 
10 days, four of the five volunteers were hospitalized with severe neurological symptoms, and 
a fifth died of brain microhaemorrages. The precise cause of death was never determined, but 
it was confirmed that all of them suffered from an acute and rapidly progressive neurological 
syndrome (Chaikin, 2017b; Kerbrat et al., 2016). No deaths in any clinical trial were 
registered since 2006. While the trial followed all clinical good practices, two mistakes of 
biochemical nature were found: a study conducted with the Activity-Based Protein Profiling 
(ABPP) technique (W. Li et al., 2007) showed that BIA 10-2474 has relatively poor 
specificity for FAAH, since it inhibits various other hydrolases including ABHD6. Also, BIA 
10-2474 is a FAAH covalent inhibitor in vitro, but this factor was not correctly considerated 
when establishing an IC50 for it, so probably the 50 mg dose gave a higher percentage of 
hydrolase blockade than the estimated 50% (Chaikin, 2017a; Van Esbroeck et al., 2017; van 
Iersel, 2017). The final report found that the drug “showed non-linear pharmacokinetics at 
doses between 40–100 mg, suggesting elimination pathways had become saturated, leading to 
accumulation” (Bégaud et al., 2016). This tragic episode taught that specificity assessment 
and accurate quantification of the inhibition are key factors to consider before clinical 
experimentation of a putative drug targeting ES regulating enzymes. The tragic BIA trial, 
however, was not the only one involving a FAAH inhibitor: another irreversible inhibitor, PF-
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04457845, has high potency and selectivity and entered a Phase II trial which went fine. The 
drug, however, gave no sign to help treating pain coming from knee osteoarthritis, so the trials 
were discontinued (Huggins, Smart, Langman, Taylor, & Young, 2012; Johnson et al., 2011). 
The major regulating enzyme for 2-AG, MAGL, is an attractive target as well, especially for 
the treatment of pain and of some kinds of cancer, and is promising for anxiety as well. 
Regarding cancer, signaling from CB receptors can in short arrest breast and prostate cancer 
cell proliferation and migration, and promote apoptosis in colorectal cancer, glioma, leukemia 
and pancreatic cancer (Fowler, 2012; Gil-Ordóñez, Martín-Fontecha, Ortega-Gutiérrez, & 
López-Rodríguez, 2018; Hermanson & Marnett, 2011). Inhibitors derivative of the carbamate 
compound URB602 have shown to inhibit melanoma cell lines proliferation and induce 
apoptotic death, with good selectivity for MAGL over FAAH and ABHD6/12 (Lauria et al., 
2018). To date, no trials involving drugs targeting MAGL or ABHD6/12 have been 
published; as said, selectivity is a key requisite for these compounds, since dual blockade of 
MAGL and FAAH has shown cannabinoid-like behavior in rats, while selective blockade of a 
single EC-degrading enzyme does not cause such behavior (Fowler, 2012). Also, complete 
inactivation of MAGL has shown to increase endocannabinoid tone and cause CB1 
desensitization, tolerance to CB1  agonists, and downregulation of CB1 receptors (Murataeva 
et al., 2014): fine tuning of the inhibition and deep understanding of the quantitative aspect of 
this inhibition are pivotal. An accurate screening of putative inhibitors is fundamental in 
discriminating the most promising compounds for successive, in-depth studies. This is the aim 
of high-throughput screening assays. 
1.1.5 High-throughput screening for hydrolases 
More than an analytical technique, high-throughput screening (HTS) is a philoshophy in 
approaching analytical problems with the aim of resolving a simple, yet complex, problem: to 
decide which items in a library, which contains them in the order of tens of thousands, are the 
most promising for an in-depth characterisation. The practice and methods of HTS assays is 
well established in the pharma industry since the early ‘90s, and has more recently started to 
be used in the academia and basic research as well. Originated to screen the most promising 
compounds to become lead ones, HTS has to deal with libraries of 10.000-100.000 
compounds (Mayr & Bojanic, 2009), which need to be screened within a  reasonable time 
frame, and with affordable costs. 
All this leads to the need of finding a reasonable compromise between the time needed for an 
assay, and the quality and costs of the analysis.  
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Among the many targets for HTS, hydrolases are a well renown one, where HTS can serve 
both for finding the most fit for the purpose mutation in a library of mutants, and for the 
identification of the most promising lead inhibitory compounds in a library of hundreds of 
thousands (Schmidt & Bornscheuer, 2005). Fluorometry is a very suitable technique for 
lipases HTS: it grants selectivity, short times and needs a relatively cheap equipment. 
Furthermore, under certain conditions it is insensitive to interferences, and allows the 
determination of lipase activity in crude cell lysates, and even in turbid solutions. Also, the 
direct observation of hydrolysis products permits the determination of the enzymatic 
inhibition according to the change in catalysis rate, rather then relying on single time point 
quantification of the product. Especially when studying the kinetic behavior of an enzyme, it 
is extremely important to use continuous assays; while practical and popular, endpoint assays 
may lead to serious misinterpretations of the enzyme activity profile. This is caused by 
accidental mistakes in fixing the T=0 point of the reaction time course, which may lead to the 
assumption of having stopped the reaction while it was still in its linear (or steady state) trait, 
when actually it was not, and subsequently underestimating the reaction velocity (Bisswanger, 
2014; Purich, 2010). Fluorometers also offer another advantage in the availability of plate 
readers using 96-well or 384-well plates, thus allowing the performing of many different 
experiments in parallel, with a minimal amount of reagents needed. The main drawback of the 
technique is that the analyte has to be a fluorescent molecule, which greatly reduces the 
spectrum of potential analytes. To date, a popular assay for hMAGL uses a fluorogenic probe 
which mimicks the natural substrate 2-AG through an arachidonic acid residue, and, 
following the hydrolysis, releases the fluorescent compound 4-methylumbelliferone (Y. 
Wang, Chanda, Jones, & Kennedy, 2008). Our group has already published an improved 
method, involving resorufin (Lauria, Casati, & Ciuffreda, 2015): this is where we started to 
develop diverse HTS assays for the screening of MAGL inhibitors. 
Moreover, a HTS assay for ABHD6/ABHD12 has been proposed (Juha R. Savinainen, Navia-
Paldanius, & Laitinen, 2016b, 2016a) and will be discussed in-depth in paragraph 5.1. Briefly, 
it involves a four-step reaction with the use of a reaction mix containing four enzymes; 
furthermore, one of the enzymatic steps relies on the quantitation on glycerol, a reagent which 
can easily come from accidental labware contamination. 
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2. AIMS OF THE STUDY  
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Our main aim was to provide means to ease the characterisation of the enzymatic hydrolytic 
system for 2-AG. The modulation of MAGL and ABHDs activity can be an important 
therapeutic target for a variety of pathologies and conditions, therefore this characterisation is 
extremely useful.  
The project is articulated in three points: 
• To develop a fluorescence HTS assay for MAGL which is efficient, fast, cheap 
and versatile, meaning it can be easily adapted to other hydrolases, exploiting 
their substrate promiscuity. 
• To design and develop a bioluminescence HTS assay for MAGL, to take 
advantage of the extreme sensitivity and specificity offered by this technique. 
• To obtain the bacterial recombinant expression of ABHD6 and ABHD12, so 
that a simpler assay could be developed (2.3.1), and the availability of the 
pure, isolated proteins might eventually lead to a better characterization, 
including the resolution of their crystallographic structures.  
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3. FLUORESCENCE ASSAY 
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3.1 Introduction 
Fluorometry (or fluorescence spectroscopy, or spectrofluorometry) is a widespread technique 
for enzyme assays, due to various advantages: it is cheap compared to other methods such as 
mass spectrometry, it does not require any specific sample preparation and, depending on the 
quantum yield of the chosen analyte, can quantify compounds in the nanomolar range. The 
classical photometric approach to the lipases assays is to synthesize an artificial ester 
substrate from a a p-nitrophenol molecule and an organic acid: since lipases usually show 
good substrate promiscuity, the enzyme will cleave the ester bond, giving a free p–
nitrophenol molecule which absorbs light at 405 nm (yellow), thus allowing a 
spectrophotometric quantification of the enzyme activity. A widespread variant consists in the 
esterification of the p-nitrophenol with phosphoric acid, obtaining a phosphate ester useful for 
the detection of phosphatase activity. While very popular in the past (Menger & Ladika, 
1987), this approach offers two major disavantages: the lower limits of quantification of 
spectrophotometric assays compared to fluorometric ones, and the intrinsic photophysical 
properties of p-nitrophenol, which make it reliable exclusively at pH values above 7.5, thus 
making its use impractical to detect the activity of enzymes at the physiological pH of 7.4 or 
lower (this despite the fact that some producers expressely claim p-nitrophenyl phosphate to 
be a suitable substrate for acid phosphatases). 
 
Figure 5. Reaction scheme for p-nitrophenol MAGL assays. The resulting free p-nitrophenol is then quantified through 
spectrophotometric reading. 
Image adapted from Pliego et al., 2015. 
 
For our MAGL-dedicated assays, we chose to use resorufin, a phenoxazine-derived 
compound which shows excellent properties for our purpose. It has a high quantum yield at 
pH 7.4, is stable in aqueous solutions and is a long-wavelength fluorophore, which emits light 
in the red region of the visible spectrum, with the emission peak at 588 nm. This is 
particularly important when long-wavelength fluorophores are employed for assays which 
involve living cells, since they avoid interferences from cellular autofluorescence (Fritzsche 
& Mandenius, 2010). In this context, resorufin compounds have a decisive advantage with 
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respect to coumarins, widely used fluorophores (fig. 6) which emit at a wavelength of about 
440-450 nm (blue-violet): the same emission wavelength of NADPH and folic acid, which 
can be found both in eukaryotic and bacterial cells (Zipfel et al., 2003). 
 
Figure 6. Reaction scheme of the short-wavelength fluorescent assay developed by Y. Wang et al., 2008. The released 
Umbelliferone is irradiated with light at λex=355 nm, and its fluorescnce is recorded at λem=460 nm. 
 
Resorufin esters as fluorescent substrates for lipases have been studied since the 1960s, and 
their high quantum yield was found to be accompanied by favorable Km values. Also, 
resorufin had proven to be an excellent leaving group with respect to p-nitrophenoxide, 
meaning faster initial “bursts” of catalytic speed. Their main disadvantages were the 
proximity of the absorption and emission peaks (small bathochromic shift) and the tendency 
to hydrolyse spontaneously once dissolved in aqueous solution (Guilbault & Kramer, 1965; 
Kitson & Kitson, 1997; Lam et al., 2012). While the small (about 60 nm) gap between the two 
peaks is no more a problem due to the spectral resolution of the contemporary 
instrumentation, spontaneous hydrolysis can be an unsormountable problem in developing an 
assay. Nonetheless, the length and shape of the size chain was found to have a role in 
spontaneous hydrolysis of these esters (Guilbault & Kramer, 1965): this was the point from 
where we started. As previously published (Lauria et al., 2015), our group had already 
successfully developed an assay using an arachidonic acid residue esterified with resorufin, 7-
hydroxyresorufinyl arachidonate (7-HRA), which showed next to none spontaneous 
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hydrolysis. But, due to the  many unsaturations, both arachidonic acid and its esters can incur 
into autoxidation (peroxidation) (Porter, 2013); also, arachidonic acid is a relatively expensive 
reagent. So we decided to explore the possibility of having a better fluorescent probe, and 
subsequently a better assay, to quantify the activity of MAGL in a quick and reliable way. 
With “better”, here we mean more sensitive, quicker, and cheaper: HTS assays need to be 
performed on a very large scale, so every saving is important when designing them. Also, we 
wanted to investigate the changes in the kinetic behaviour of MAGL according to variations 
in the alkylic side chain of its substrates. Finally, we wished to interpret the experimental data 
analysing the structural aspects of the enzyme-substrate interaction through in silico analysis, 
with the aim of finding new structural guidelines for the optimisation of MAGL substrates 
and inhibitors. To pursue these aims, we decided to synthesize ten alkyl esters of fluorogenic 
resorufin with different types of acyl chains: linear, employing acetate (1a), butyrate (1b), 
octanoate (1c), dodecanoate (1d), icosanoate (1e), oleate (1f); branched, including 2-
methylhexanoate (1h), 2-ethylhexanate (1i) and 2-butyloctanoate (1j); and aromatic, using 
benzoate (1k) (fig.7). The behavior of these esters as fluorescent substrates for the 
measurement of MAGL activity was to be evaluated, as well as their structural relationships 
with the enzyme using a docking software. 
  
Figure 7. Structures of 7-hydroxyresorufynil-acetate (1a), butyrate (1b), octanoate (1c), dodecanoate (1d), icosanoate (1e), 
oleate (1f), arachidonate (1g), 2-methylhexanoate (1h), 2-ethylhexanate (1i) and 2-butyloctanoate (1j), and benzoate (1k). 
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3.2 Results and discussion 
3.2.1 Synthesis of substrates 
Syntheses of 7-hydroxyresorufinyl-derivatives 1a-1k were performed by conversion of 
opportune carboxylic acid in the corresponding acyl chloride, using oxalyl chloride and DMF 
in dry CH2Cl2 following the classic method for acyl chloride formation in neutral conditions. 
Treatment of carboxylic acid with 2.0 equiv. of oxalyl chloride in dry CH2Cl2 with catalytic 
amount of DMF resulted in slow gas evolution over a period of 3 hours. Removal of the 
solvent and exposure of the resulting acyl chloride to free phenol form of resorufin in dry 
CH2Cl2 with triethylamine gave the desired compounds in yields varying from 65 to 92 % 
(3.4, Table 3). 
Resorufin esters 1h, 1i, and 1j instead, could be conveniently prepared by the DMAP-
catalyzed DCC method (Steglich esterification (Neises & Steglich, 1978)). The yields are 
considerably higher than those obtained in the non-catalyzed reaction. With this method, a 
solution of the acid was prepared in anhydrous CH2Cl2, to which resorufin and DMAP were 
added. Then DCC was added to the reaction mixture at 0 °C at the same final concentration as 
the acid, and the obtained solution stirred for 3 h at room temperature. 
The possibility of synthesizing esters of 1h, 1i, and 1j reaches a limit with more bulky, i. e. 
sterically hindered carboxylic acids. Thus, in the case of 2-methylhexanoic acid, 2-
ethylhexanoic acid and 2-butyloctanoic acid, the symmetrical anhydrides were isolated 
instead of the esters and the tendency for undesirable N-acylureas to be formed was observed. 
In the Steglich esterification, the addition of 3 mol % DMAP accelerates the DCC-activated 
esterification of carboxylic acids with alcohols to such an extent that formation of side 
products is suppressed and even sterically demanding esters are formed in good yields at 
room temperature. 
Unambiguous assignments of protons and carbons were recognized by 1D NMR spectra, as 
well as 2D NMR homocorrelation (COSY) and heterocorrelation (HMQC and HMBC) 
spectra were employed for complete structural assignments. The 1H-NMR and 13C-NMR 
spectra are reported in the Appendix (Table 7). The purity of all compounds measured with 
NMR was greater than 98%.  
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3.2.2 Assay development and validation 
To obtain proof-of-concept for the compounds newly synthesized (1a-k), in MAGL assays, 
reaction conditions close to that reported by Lauria et al (Lauria et al., 2015) were chosen; in 
the cited study, the amount of enzyme used in the assay was already optimized to 25 ng to 
maintain linearity over time and to maintain substrate consumption below 10%, adhering to 
the assumptions of the Michaelis–Menten equation. 
The substrates were readily dissolved in DMSO to make 1.0 mM stock solutions, which were 
further diluted with DMSO to 50 µM working solutions. The exception to this was substrate 
1e, which could not be dissolved in DMSO and was excluded from further studies. Good 
reproducibility was obtained by making “assay substrate solutions” from slowly adding the 
buffer to the DMSO working solution until a final concentration of 5 µM substrate. There was 
no sign of turbidity or precipitation of substrate under any conditions. For characterization of 
surrogate substrates 1a-k we chose the commercially available human recombinant enzyme 
MAGL (Cayman Chemical) to have a known reference activity independent from the 
variability of cell extracts. Typical MAGL assays use bovine serum albumin (BSA) since it 
assists in the solubility of the substrate and might prevent the non-specific binding of the 
substrate to the walls of the tubes (Y. Wang et al., 2008). We, however, decided not to use 
BSA because of its reported esterase-like activity (Sakurai et al., 2004). Results of activity 
assays for all substrates are shown in fig. 8, and indicate enzyme activity and stability of the 
substrates. 
MAGL hydrolyzed a variety of resorufin derivatives with a distinct substrate preference (fig. 
8). Of all the compounds newly synthesized, the fastest one was found to be 1c (Table 2). Of 
the others, six compounds (namely 1a, 1b, 1c, 1d, 1f, 1h) proved to be “proper” substrates for 
MAGL, while 1i, and 1j showed a very low hydrolytic activity, but were subsequently 
characterized nonetheless, and 1k did not show an hydrolytic activity at all (fig. 8). Substrate 
1k was therefore excluded from further investigations. 
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Figure 8. time course of surrogate substrates 1a, 1b, 1c, 1d, 1f, 1h, 1i, 1j and 1k hydrolysis by MAGL. 25ng/well 
of human recombinant MAGL (circles) or buffer alone (empty squares) were incubated in 96-well black plate, at 
room temperature, with 5 µM for all compounds in total volume of 100 µL per well, as described in the 
experimental section (3.4). Fluorescence was measured at indicated time points using a Jasco FP-8300 
fluorometer using the kinetic mode (λex=571 nm, λem=588nm, slit = 5.0). Data are mean ± standard error of 
independent experiments. The data reported represent one data point every two, in order to grant readability of 
the graphs. 
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Enzyme kinetics were analyzed by measuring 
initial product formation rates in the presence of 
varied substrate amounts, the maximal value set 
according to solubility limits. In order to obtain 
the fluorescence coming from the enzymatic 
activity substrate depletion was determined by 
establishing the amount of free resorufin produced 
using a resorufin standard curve, and subtracting 
the amount of free resorufin released at the same 
time from the spontaneous hydrolysis of the 
substrate. For this purpose, standard curves showing fluorescence response vs 
substrate/product concentration, were constructed from five concentrations of resorufin (fig. 
9).  
The initial linear trait of the resulting curve was taken into account, and its slope was 
considered as the measure of enzyme activity (Bisswanger, 2014). Concentrations ranging 
from 0.5 µM to 25 µM were used. 
Figure 9. The typical resorufin standard curve. The 
values represent the average of triplicate values ± 
SD. Resorufin concentrations were 0, 0.01, 0.1, 0.5, 
1, and 5 µM. 
Figure 10. Action of human recombinant MAGL on different concentrations of surrogate substrates 1a, 1b, 1c, 1d, 1f, 1h, 1i, 
and 1j, in the presence of DMSO (10%, v/v). The reactions were conducted in a final volume of 50 mM Tris-HCl buffer (pH 7.4, 
1 mM EDTA) with 25 ng/well of MAGL. Values are the means of triplicates ± standard error. The kinetic parameters Km and 
Vmax were determined via computer-assisted nonlinear regression analysis using GraphPad Prism 6.0c. 
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Compound LogD at pH 
7.4a 
Km (µM) Vmax 
(nmol/min/mg 
protein) 
Docking score MM-GBSA 
1a 1.69 n/a n/a -6.7 -52.4 
1b 2.83 n/a n/a -7.7 -60.5 
1c 4.61 0.96 ± 0.20 
 
126.13 ± 9.86 
 
-8.2 -72.0 
1d 6.39 0.44 ± 0.17 
 
28.22 ± 3.78 
 
-10.5 -81.4 
1e 9.94 n/a n/a -9.8 -67.8 
1f 8.69 0.38 ± 0.10 
 
12.74 ± 0.67 
 
-10.8 -73.2 
1g 8.50 0.87 ± 0.13 
 
25.84 ± 0.88 
 
-10.7 -76.0 
1h 4.26 1.68 ± 0.60 
 
46.21 ± 6.89 
 
-8.5 -60.3 
1i 4.71 n/a! n/a! -8.8 -62.8 
1j 6.49 0.98 ± 0.19! 0.73 ± 0.03! -8.4 -65.4 
1k 3.74 n/a! n/a! -8.9 -63.2 
2-AG 4.56 110 ± 15a 120 ± 10a -10.4 -53.1 
Resorufin calibration curves and negative controls, containing 90 µl of buffer, 10 µl DMSO 
and no MAGL, were measured at the same time and in the same conditions. Fig. 9 illustrates 
the action of human recombinant MAGL on different concentrations of all synthetized 
substrates in the presence of DMSO (10%, v/v). 
Compound 1a and 1b did not behave in a Michaelis-Menten way under the assay conditions, 
while the catalytic speed 1f, had a sharp decrease at concentrations above 10 µM. The Prism 
software was not able to calculate kinetic constants for 1i (fig.10). Since MAGL hydrolytic 
activity on this enzyme was very limited, we did not investigate its kinetic properties further.  
All substrates have Km values ranging from 0.44 to 1.68 µM, which seem in accordance to 
that of 0.87 µM already calculated for 1g (Lauria et al., 2015). Maximum velocities are 
similar as well, ranging from 12.74 to 46.21 nmol/min/mg protein, values which resemble that 
Table 2. Kinetic values, lipophily, expressed as LogD, and docking scores (3.2.4) of the resorufin moieties in the assay 
conditions. 
a: data from Navia-Paldanius et al., 2012 
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of 26 nmol/min/mg protein calculated for 7-HRA. The notable exception to this is compound 
1c, with a Vmax of 126 nmol/min/mg protein (fig. 10). 
In order to validate our method for use in enzyme inhibition assay two known MAGL 
inhibitors, URB602 and MAFP (King et al., 2007; Saario, Savinainen, Laitinen, Järvinen, & 
Niemi, 2004), were assessed using the standard assay conditions with 5 µM 1c as substrate 
and DMSO as solubilizer to validate the ability to identify inhibitors. The dose–response 
curves are shown in fig. 11. 25 ng/well of MAGL were incubated at room temperature for 60 
minutes at 25 °C with different concentrations of inhibitor dissolved in DMSO; after the rapid 
addition of 1c solution, the fluorescence was measured every minute for a period of 1 hour. 
The activity of MAGL was calculated as described for the kinetic assay.  
 
Figure 11. Inhibition of human recombinant MAGL with reference inhibitors: methyl arachidonyl fluorophosphonate 
(MAFP) (a), URB602 (b). Data derived from two independent experiments performed in triplicate and calculated as non 
linear regressions using sigmoid dose-response setting with variable Hill slope by GraphPad Prism 6.0c. 
IC50 for URB602 was found to be 8.1±2.6 µM, which is in line with literature data (Matuszak, 
Muccioli, Labar, & Lambert, 2009). As already known, MAFP had the lowest IC50 value, 
15.3±3.7 nM, which is in the range of values indicated in different works (Lauria et al., 2015; 
Matuszak et al., 2009). Data derived from two independent experiments performed in 
triplicate and calculated as non linear regressions using sigmoid dose-response setting with 
variable Hill slope by GraphPad Prism 6.0c. These data confirm that the assay is able to 
identify MAGL inhibitors appropriately. 
3.2.3 Suitability for cell hydrolase imaging 
1c cannot be considered specific for MAGL (Kapoor & Gupta, 2012); however, the use of 
fluorescent substrates can be useful for the study of unspecific lipase activity within the cell 
(Kim, Kim, Choi, & Kim, 2015), especially if long-wavelength substrates such as resorufin 
are used (see 2.1.1). To assess the potential of 1c to act as a reporter of hydrolase activity in 
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living cells, B16-F10 melanoma cell lines, a cancer cell line known to express MAGL, were 
used (Lauria et al., 2018). 
The cells were cultured to convergence in 6-well plates, then they were incubated with 5 mM 
1c in DMSO (1µl/1 mL culture medium, final concentration 1‰ DMSO, 5 µM substrate) for 
5 minutes. A negative control was set at the same time, using DMSO in the same quantity, but 
with no substrate dissolved into it. After these 5 minutes, the culture medium was removed 
from the wells, then 1 mL of fresh medium was pipetted onto that. The procedure was 
repeated twice, to ensure that any residual substrate was washed away. The wells were then 
examined at the fluorescence microscope, using a green (530-550 nm) excitation filter. 
  
Figure 12. B16-F10 melanoma cell lines after 5 minutes incubation with substrate 1c, at 10x magnification. The pictures 
show the same well area, both under phase contrast light (left) and in fluorescence mode (right). Our fluorescent substrate 
shows its capability to enter the cell and to be hydrolyzed by cell lipases. 
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3.2.4 In silico molecular docking simulations 
The identified binding site corresponds to the catalytic active site identified by Lauria et al 
(Lauria et al., 2015). 
Table 2 (3.2.2) reports the Glide XP docking score and MM-GBSA binding energies for the 
top scoring pose of each tested compound, showing that all of them are able to bind MAGL in 
its catalytic site. Docking simulations provided overlapping poses for all the tested 
compounds and a good superposition of their common resorufin group (fig. 13), confirming 
the accuracy of this approach. Moreover, the carbonyl group for all the tested compounds, 
except for 1j, overlaps the carbonyl group of the natural substrate 2-AG in proximity to 
Ser122, according to Lauria et al (Lauria et al., 2015).  
Both the Glide XP and MM-GBSA results suggest that 4 compounds (1c, 1d, 1f, 1g) can be 
classified as good MAGL ligands. In particular, compounds 1d, 1f, 1g are associated to a 
lower Glide XP value than the 2-AG one. Their linear side chains mimic that of a natural 
MAGL substrate, showing the same orientation into the MAGL hydrophobic pocket. 1c 
Figure 13. Docking poses of tested compounds, as well as of the native substrate 2-AG, into the MAGL active site. MAGL is 
shown in ribbon representation; tested compounds and Ser122 are shown as stick representation. All ester oxygen atoms can be 
seen as headed towards the catalytic Ser residue, except for compound 1j, in accordance with the experimental results (see 
text). 
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mimics 2-AG, but it is shorter than it and it does not present a turn of its side chain in its 
binding pose (fig. 13). Moreover, these 4 compounds have a MM-GBSA binding energies 
lower than 70 kcal/mol, outstripping the other ones of approx. 10 kcal/mol (Table 2). 
Branched side chains compounds 1h-j, 1k and short linear side chain compounds (1a, 1b) can 
be classified as weak binders, considering both Glide XP and MM-GBSA scores. Among 
them, 1j is the unique compound with a carbonyl group which does not overlap the reference 
2-AG position due to effect of its branched side chain placement. 1e, that has a linear side 
chain composed by 20 carbons, shows intermediate values of both Glide XP and MM-GBSA 
scores. 
Globally, compounds with linear side chains longer than 8 carbons fit the MAGL 
hydrophobic pocket better than compounds with branched/aromatic side chains, while 
compounds with linear side chains shorter than 6 carbons are penalized in binding. 
3.3 Conclusion 
We have readily synthesized long-wavelength putative fluorogenic substrates characterized by 
different acylic side chains and applied them to the fluorometric determination of MAGL 
activity. The relationship between the structure of alkyl esters of fluorogenic resorufin and 
their different behaviors towards MAGL was examined. An in-silico evaluation of how these 
different side chains interact with the active site of MAGL has been performed as well. 1c, 
was found to be a better substrate than their homologs for the fluorimetric assay of MAGL, 
being the substrate with the higher rate of hydrolysis and the best Km and Vmax values. 1c 
looks way better than 7-HRA (1g) since, containing an eight carbon atoms unbranched chain 
instead of a twenty carbon one, has higher water solubility, making its use in screening easier, 
is cheaper and provides a higher sensitivity. The test assay using 1c was validated using the 
well-known MAGL inhibitors URB602 and MAFP. 
The method described in this section can act as an interesting tool for the HTS screening of 
MAGL modulators. The octanoyl resorufin substrate proved to be the best candidate in this 
assay, since, due to the lack of long hydrocarbon fatty acid chains with rather unstable cis 
olefines, it is a very stable compound in aqueous solution, and is easily prepared with a 
simply scalable technique. Kinetic and modeling data also demostred that, comparated with 
known fluorescence-based MAGL assay, our method is the quickest and the cheapest one 
available.  
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3.4 Experimental section 
Reagents and materials 
Monoacylglycerol lipase (human recombinant, 50 µg) was purchased from Cayman Chemical 
(Ann Arbor, MI, USA). Arachidonic acid, resorufin, Tris, ethylendiaminetetraacetic acid 
(EDTA), Hepes, phosphate buffered saline (PBS) tablets and all other reagents and solvents 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Reactions progress was 
monitored by analytical thin-layer chromatography (TLC) on pre-coated aluminum foils 
(Silica Gel 60 F254-plate, Sigma-Aldrich) and the products were visualized by UV light. All 
steps which included resorufin were carried out protecting the compound from light from that 
step on. 
Instruments 
Fluorescence signals were recorded by a Jasco FP-8300 fluorometer (Jasco, Tokyo, Japan) 
using the kinetic mode (λex=571 nm, λem=588nm, slit = 2.5 nm in both cases) with flat bottom 
96-well black plate. 
1H-NMR spectra were recorded in CDCl3 (isotopic enrichment 99.95%) solutions at 300 K 
using a Bruker AVANCE 500 instrument (500.13 MHz for 1H, 125.76 MHz for 13C) using 5 
mm inverse detection broadband probes and deuterium lock. Chemical shifts (d) are given as 
parts per million relative to the residual solvent peak (7.26 ppm for 1H) and coupling 
constants (J) are in Hertz. The experimental error in the measured 1H-1H coupling constants is 
± 0.5 Hz. The splitting pattern abbreviations are as follows: s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet, and bs, broad peak. Unambiguous assignments of protons and carbons 
were recognized by 1D NMR spectra, as well as 2D NMR homocorrelation (COSY) and 
heterocorrelation (HMQC and HMBC) spectra were employed for complete structural 
assignments. For two-dimensional experiments, Bruker microprograms using gradient 
selection (gs) were applied. 
Synthesis of 7-hydroxyresorufinyl-derivatives 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h 
To a solution of opportune carboxylic acid (0.46 mmol) in dry CH2Cl2 (2 mL), oxalyl chloride 
(58 µl, 0.69 mmol) in dry CH2Cl2 (0.5 mL) was added dropwise at 0 °C under stirring. N,N-
dimethylformamide (DMF, 1 drop) was added next. The reaction mixture was stirred at room 
temperature for 3 h and then concentrated under vacuum, giving crude acyl chloride. This 
residue was dissolved in dry CH2Cl2 (1 mL) and added dropwise to an ice-cold suspension of 
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resorufin (50 mg, 0.23 mmol) and triethylamine (48 µl, 0.35 mmol) in dry CH2Cl2 (3 mL) and 
then stirred overnight at room temperature. After dilution with CH2Cl2 the salts residues were 
removed by filtration obtaining a brick-red solution; that was washed with 0,5 M HCl (2 mL), 
saturated NaHCO3 (2.5 mL), dried on anhydrous Na2SO4 and concentrated to give the crude 
product. Column chromatography on silica gel by a suitable mobile phase gave the desired 
compounds in yields varying from 62 to 92 %. The purity of all compounds measured with 
NMR was greater than 98%. . LogdD data were generated using the Chemicalize ChemAxon 
software, https://chemicalize.com/. 
Synthesis of resorufin esters 1h, 1i, 1j 
To a stirred solution of opportune carboxylic acid (0.46 mmol) in dry CH2Cl2 (3 mL), was 
added DMAP (2.5 mg. 0.02 mmoli) and resorufin (50 mg, 0.23 mmol). DCC (72 mg, 0.35 
mmoli) was added to the reaction mixture at 0 °C. Stirring was continued for 5 min at 0 °C 
and for 3 h at 20 °C. Precipitated urea is then filtered off and the filtrate evaporated down in 
vacuo. The residue was taken up in CH2Cl2 and, if necessary, filtered free of any further 
precipitated urea. The CH2Cl2 solution was washed twice with 0.5 M HCl (2 mL), saturated 
NaHCO3 (2.5 mL), dried on anhydrous Na2SO4 and concentrated to give the crude product. 
Products can be obtained in pure form by filtration on column chromatography on silica gel 
by a suitable mobile phase. The desired compounds were obtained in yields varying from 82 
to 92 %. LogdD data were generated using the Chemicalize ChemAxon software, 
https://chemicalize.com/. 
Table 3. Mobile phases used for the separation of synthesis products. 
Compound Yield Mobile phase m.p. 
1a 65% CH2Cl2/acetone, 98:2 225-226 °Ca 
1b 
 
71% 
Petroleum ether/AcOEt gradient, from 
7:3 to 5:5. 
146-147 °Ca 
1c 68% Petroleum ether/AcOEt 8:2. 111-112 °C 
1d 72% 
Petroleum ether/AcOEt gradient, from 
8:2 to 7:3. 
117-119 °C 
1e 75% CH2Cl2/acetone, 98:2 124-125 °C 
1f 66% Petroleum ether/AcOEt 8:2. 82 °C 
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1g 62% CH2Cl2/acetone, 98:2 Oila 
1h 90% Petroleum ether/AcOEt 75:25. 144-145 °C 
1i 82% CH2Cl2/acetone, 98:2 124-125 °C 
1j 92% CH2Cl2/acetone, 98:2 94-96 °C 
1k 92% 
Petroleum ether/ AcOEt 9:1 to remove 
side products, then CH2Cl2/acetone 
98:2. 
241-242 °Cb 
 
a  Guilbault & Kramer, 1965 
b Lauria et al., 2015 
 
Stability of the substrate 
The stability of all substrates was tested in 50mM Tris-HCl buffer (pH 7.4, 1 mM EDTA), 
according to our previous results (Lauria et al., 2015). 
10 µl of the substrates dissolved in DMSO (final concentration 5 µM) were added to 90 µl of 
the buffer. The fluorescence increase at 588 nm was monitored at intervals of 1 minute across 
an incubation period of 90 minutes at controlled room temperature of 25 °C, using a Jasco FP-
8300 fluorometer in kinetic mode (λex=571 nm, λem=588nm, slit = 5.0 nm in both cases) 
(Jasco). 
Substrates screening  
The assays were performed on a 96-well plate. MAGL activity was monitored following the 
increase of resorufin fluorescence (λex=571 nm, λem=588nm), at intervals of 1 minute. Each 
reaction well contained 80 µl Tris-HCl 50 mM with EDTA 1 mM, 10 µl of buffer with 25 ng 
MAGL and the putative substrate dissolved in 10 µl of DMSO (final concentration 5 µM), 
total volume 100 µl (Lauria et al., 2015). The measurements were carried at a controlled room 
temperature of 25 °C. Resorufin calibration curves and negative controls, containing 90 µl of 
buffer and no MAGL, were measured at the same time and in the same conditions. All 
experiments were performed in triplicate, and each experiment was independently replicated 
at least once. All resorufin ester solutions were freshly prepared in DMSO from powder, then 
divided into aliquots and stored at -80 °C, to be used without any further freeze-thaw cycle. 
Kinetic assays of MAGL. 
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For all assays, MAGL was diluted to 250 ng/mL in 50 mM Tris-HCl buffer (pH 7.4), with 
1mM EDTA (reaction buffer). For each substrate concentration (0.5 µM, 1 µM, 2.5 µM, 5 
µM, 10 µM, 25 µM and 50 µM), a reagent solution was prepared by diluting first at 5 mM 
dimethyl sulfoxide (DMSO) stock in DMSO to 5 µM, 1 µM, 25 µM, 50 µM, 100 µM, 250 
µM and 500 µM solutions, then by diluting these solutions 1:10 in reaction buffer to obtain 
reagent solutions. The enzyme preparation was added in triplicate (10 µl) to wells in a black, 
flat-bottomed, 96-well polystyrene microtiter plate (BD Falcon). Each reagent solution (90 µl) 
was added to the wells to a final concentration of 0.5 µM, 1 µM, 2.5 µM, 5 µM, 10 µM, 25 
µM and 50 µM. The final MAGL concentration was 25 ng/100 µl (7.6 nM), and the final 
DMSO concentration was 10%. 
To assess the fluorescent signal coming from the substrate with no enzyme added, negative 
controls were performed in the same way as above and in triplicate, but 10 µl of reaction 
buffer were added instead of enzyme preparation. A blank sample containing no enzyme (90 
µl of reaction buffer, 10 µl DMSO) was also prepared in triplicate wells. Fluorescence was 
measured in the same instrumental conditions as per the substrates screening, for 40 cycles 
with a cycle time of 1 min. All readings were performed in triplicate and averaged. A standard 
curve was generated by plotting fluorescence of five concentrations of resorufin (0.01 µM, 0.1 
µM, 0.5 µM, 1 µM, 5 µM) prepared by diluting DMSO stocks in reaction buffer and adding 
to microtiter plate wells in triplicate (100 µl, final DMSO concentration 10%). All readings 
from triplicate wells were averaged.  
Data analysis. 
Fluorescence was measured and recorded as above. The mean fluorescence value of a blank 
was subtracted from the value of each sample and control well to normalize data at each time 
point, then the mean value of control wells was subtracted to the mean value of corresponding 
enzyme wells. The curve generated from the standards was used to convert raw fluorescence 
data into nmol/mL/min of resorufin produced. The values of the curve coming from wells 
with the substrate without the enzyme were subtracted from the enzymatic curve: initial 
velocities were determined from the linear portion of the resulting curve. Kinetic data were 
elaborated using GraphPad Prism 6.0c (GraphPad Software, San Diego, CA, USA) and 
Microsoft Excel graphing software; kinetic parameters Km and Vmax were calculated using 
GraphPad, employing a nonlinear regression analysis (substrate inhibition or Michaelis-
Menten, according to best fit). The quantitative data were calculated as means ± standard 
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errors. The Z’-factor was calculated using the equation Z!=1-(3σh+3σl)/|µh-µl|, where σh and 
σl are the standard deviations of the high and low signal controls, respectively, and µh and µl 
are the mean signal intensities of the high and low signal controls, respectively (Zhang Ji-Hu, 
Chung Thomas D.Y., 1999). 
Continuous assay using known MAGL inhibitor 
Methyl arachidonyl fluorophosphonate (MAFP) and URB602 were chosen for the method 
validation (King et al., 2007; Saario et al., 2004). Diluted MAGL (10 µl) was added to 27 
wells in a black, flat-bottomed, 96-well polystyrene microtiter plate. Inhibitor solutions were 
added to wells at eight different concentrations in triplicate, and well volume was adjusted to 
95 µl with reaction buffer. A set of triplicate wells received no inhibitors, and well volume 
was adjusted to 95 µl with reaction buffer. Final concentrations of MAFP were 1.00 µM, 500 
nM, 100 nM, 50.0 nM, 10.0 nM, 5 nM, 0.1 nM, and 0.00 nM; final concentrations of URB602 
were 75 µM, 50 µM, 25 µM, 10 µM, 5 µM, 1 µM, and 100 nM. A 100 µM substrate reagent 
solution was prepared by diluting a 5 mM DMSO stock 1:50 in DMSO. After 60 mins of 
incubation at 25 °C, 5 µl of the substrate reagent solution was added to each well to give a 
final substrate concentration of 5 µM. The final concentration of enzyme in all wells was 0.76 
pM and the DMSO concentration was 10%. A blank sample containing no enzyme (90 µl of 
reaction buffer, 10 µl DMSO) was also prepared in triplicate wells. Instrument settings were 
the same used for the substrates screening. Fluorescence was recorded at room temperature 
for 30 cycles, with a cycle time of 1 min. All readings were performed in triplicate and 
averaged. The mean fluorescence value of a blank was subtracted from the value of each 
sample and control well to normalize data at each time point then the mean value of control 
wells was subtracted to the mean value of corresponding enzyme wells. IC50 was determined 
as the concentration of inhibitor that results in an initial velocity 50% that of the sample 
containing no inhibitor. IC50 was used along with previously calculated Km to determine Ki. 
In-silico molecular docking simulations 
All the computational procedures were carried out by the Schrödinger Small-Molecule Drug 
Discovery Suite 2018-01. The crystallographic structure of the core domain of human MAGL 
was downloaded from the RCSB PDB (PDB ID: 3PE6, resolution of 1.35 Å) (Schalk-Hihi et 
al., 2011) Schrödinger Protein Refinement tool was used to mutate Ala36, Ser169 and Ser176 
in Lys36, Leu169 and Leu176, respectively. The wild-type MAGL structure was then energy 
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minimized using the Schrödinger Protein Preparation Wizard in order to fix structural issues 
in the three-dimensional (3D) structure. 
Tested ligands were built through the Schrödinger Maestro Build Toolbar and prepared for 
docking by the Schrödinger Ligand Preparation, generating the stereoisomers of 1b, 1i and 
1h. 
The molecular docking procedure was carried out by the Schrödinger Glide Docking in the 
“extra precision (XP)” mode in order to evaluate the ability of the tested ligand to bind the 
MAGL catalytic domain, keeping only the twenty top-scoring poses. 
The top-scoring solution for each ligand was submitted to the Schrödinger Prime MM-GBSA, 
which integrates molecular mechanics energies combined with the generalized Born and 
surface area continuum solvation (Genheden & Ryde, 2015) in order to compute ligand 
binding and ligand strain energies for a set of ligands and a single receptor. 
 
 
 
 4. BIOLUMINESCENCE ASSAY 
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4.1 Introduction 
Bioluminescence (BL) is a form of chemiluminescence (CL) (the emission of visible 
light produced by a chemical reaction) produced by an organism. There are many 
reasons for which different organisms have evolved BL several times: in the depths of 
the oceans, an environment where BL is extremely widespread, potential preys did not 
have many choices but to reach the deepest waters, where the darkness would have hid 
them from the sight of their predators. Here, light-emitting organs help them to find 
mates, or to escape predators through a wide array of tactics: producing a flash of BL to 
blind or distract their stalker (some animals can even detach bioluminescent parts of 
their body to distract their chaser), discouraging the predator through the menace of 
sticking bioluminescent tissues to its body (so that other predators will easily localise 
it), or emitting an ambient-like light from their bellies so that the predator swimming 
under them will not see their shadow against the dim sunlight above2. On the other 
front, BL can serve to find preys for their bearers, illuminating or attracting them. In 
other environments, where the landscape provides plenty of hideouts, BL is rarer: in 
freshwater it is almost absent, while on land it is of domain almost exclusively of 
insects, and serves mostly for mating. This extreme variety helps to explain why the 
emission of BL from WT luciferases can cover a lot of different wavelengths: 
underwater, the blue light is the one which travels furthest, and thus is the most 
widespread (although examples of specially evolved red light emission are present in 
the oceans as well among predatory fishes (Herring & Cope, 2005)), while on land the 
most present is green-yellow light, since leaves reflect it best (Widder & Falls, 2014).  
The main differences with respect to CL reactions lie in the mechanism and the yield of 
the reaction. With respect to the mechanism, BL is the result of a biochemical oxido-
reduction between an enzyme, a luciferase, and a substrate, a luciferin. These are very 
generic names, so different biochemical systems are usually differentiated by the use of 
a taxon prefix, e.g. “PpyWT” generally stands for “Wild-type luciferase from the 
Photinus pyralis firefly”. It is important to bear in mind that bioluminescent systems 
found in different organisms are based on luciferase-luciferin systems which vary 
                                                
2 This strategy, named “counterillumination”, is epitomized by a group of cephalopods known as “bobtail squids”: 
the squid Euprymna scolopes is symbionts with the bioluminescent bacterium Aliivibrio fischeri, which they host 
inside a specialised organ, providing the bacteria a sugar and aminoacid solution. The organ can also regulate the 
wavelength, intensity and direction of the light produced by the bacteria, so that the light matches perfectly that of the 
above sky condition and hour of the day. 
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widely from one another.  Moreover, BL reactions usually have a much higher quantum 
yield than CL ones: e.g. the PpyWT luciferase has a quantum yield of 0.48 at pH 8.0, a 
much higher value than that of any CL reaction (Niwa et al., 2010). The first important 
advantage of BL as an analytical technique directly descends from its mechanism: 
specificity. The luciferase can emit a luminescent signal exclusively if it reacts with its 
specific luciferine and cofactors, with no other possible causes other than technical 
problems (e.g. the detector is exposed to light coming from a different source). The 
second one is sensitivity: CL reactions in general offer interesting sensitivity, with the 
capability to detect attomoles of analyte in solution even with quantum yields as low as 
0.01 (Roda et al., 2016). Combined with the high quantum yields of BL, this makes the 
use of luciferases the most sensitive methods of detection available, while keeping the 
costs for the instrumentation relatively low. The firefly luciferase/luciferin are the most 
sensitive methods of detection available, with detection capabilities down to 10-17 mol 
(tens of attomoles), to the point that the ATP emission from a single bacterial cell can 
be detected via BL (Roda et al., 2016; Satoh, Kato, Takiguchi, Ohtake, & Kuroda, 
2004). Luciferases catalyse an oxido-reductase reaction, which requires oxygen and, 
when the reaction occurs within the cellular environment, a cofactor: these include Ca2+ 
in jellyfishes, Mg2+ and ATP in fireflies, H+ in dinoflagellates, H2O2 in earthworms, 
FMNH2 and NADH in bacteria, cyanide ions in Bermuda fire worms, and ferrous ions 
in parchment tube worms (Widder & Falls, 2014). The necessity of these cofactors can 
be conveniently exploited in the detection of these small molecules. 
Figure 14. The classic proposed firefly luciferase-luciferin reaction scheme (White, Rapaport, Seliger, & Hopkins, 
1971). Through the use of an ATP molecule in the presence of a magnesium atom, the luciferase produces D-
luciferyl adenylate (2). The subsequent reaction of LH2-AMP with O2 brings to the release from luciferase of a 
dioxethanone product (3), which decarboxylates spontaneously to produce Oxyluciferin in an electronically excited 
state; the thiazole oxygen atom then relaxes through the release of a photon, yielding Oxyluciferin (4). 
Dehydroluciferin (6), a product of luciferin degradation, acts a luciferase inhibitor, since its derivative 
dehydroluciferyl adenylate (5) is unable to react with oxygen, and subsequently to leave the enzyme active site. 
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In the case of firefly luciferase, it oxidizes firefly luciferin to oxiluciferin through a key 
dioxietanone intermediate; spectroscopic data show the involvement of a superoxide 
anion in the formation of this dioxietanone through a single-electron transfer 
mechanism (Branchini, Behney, et al., 2015). The reaction is strongly stereospecific for 
D-luciferin: L-luciferin is an inhibitor of the light-emitting reaction, as is the 
oxyluciferin product. The fact that the reaction is inhibited by its product is thought to 
cause the “flash” pattern of firefly luciferase light emission, in lieu of the continuous 
“glow” emission seen in bioluminescent bacteria, which work on a totally different 
mechanism based on FMNH2 and a long-chain aliphatic aldehyde (Pinto Da Silva & 
Esteves Da Silva, 2014; Widder & Falls, 2014). A common application which involves 
the use of BL is probing, in cellular biology and living tissues in general, or 
biophotonics: in these cases, BL offers the additional advantage of being non-
destructive and non-lethal for the tissues and organisms being studied. Luciferases can 
be used directly to quantify enzymatic reactions through the quantification of reaction 
products or to detect other small molecules, like ATP or NADPH, cells can be 
transfected with luciferase genes to analyse gene espression in tissues and organisms, or 
disease progression in animal models, and bioluminescent bacteria can be employed to 
map and quantify environmental pollutants (Widder & Falls, 2014). Last but not least, 
many diverse biosensoristic techniques employ CL and BL as means of detection (Roda 
et al., 2016), and the possibility to develop luciferase fusion proteins further expands the 
potential field of application (Smirnova & Ugarova, 2017). The monitoring of 
bioluminescent tissues in living animals, such as xenographs transfected with luciferase 
genes, is a well-established practice (Feng et al., 2016; Ke et al., 2016). Cell-based 
assays on 96- and 384-well plates can be more convenient to the point of being suitable 
for HTS assays, even if in some cases the actual trasferability to automated practices 
has yet to be proven (Michelini, Cevenini, Calabretta, Calabria, & Roda, 2014).  
Assessment of enzymatic activity in vitro through BL is not fully developed yet, but it 
looks like a promising field of application, with a few examples of ingenious methods 
studied to exploit the potential of BL, especially for transferases (Ibáñez, McBean, 
Astudillo, & Luo, 2010; Lin et al., 2018). Regarding hydrolases, the two main strategies 
for detection remain those of indirect determination of the enzyme activity targeting 
byproducts of the enzymatic reaction (strategies depend on the reaction), and the 
“caging” of the luciferin in an artificial substrate, which releases free luciferin after the 
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hydrolytic reaction occurs (J. Li, Chen, Du, & Li, 2013). Pros and cons of these two 
strategies remain mostly the same as fluorescence strategies using artificial probes, but 
with important additions. The added “pros” are those typical of BL in general, which 
means enhanced selectivity and sensitivity; these are traded for the need of an additional 
enzyme, which brings additional costs to the analytical setup and the risk of the 
luciferase being inhibited by the putative hydrolase inhibitors, adding false positives to 
the screening results. This last point in particular is very delicate: although the 
differences in catalytic mechanism and structure between luciferases and hydrolases 
should minimize the number of false positives, we already know that PpyWT is 
inhibited by 4-10% of the chemicals found in a typical library (Michelini et al., 2014), 
and there can be no way to completely avoid this phenomen, but testing the chosen 
luciferase for known hydrolase inhibitors during the assay development is a good idea 
(Lin et al., 2018). 
Aim of this work was to try and develop a screening assay for MAGL inhibitors using 
BL as detection method. A major issue in this case is that of luciferase stability: 
preliminary experiments from our group have shown that Lit/PpyWT luciferase does 
not work in the assay conditions already established for MAGL (Lauria et al., 2015). 
The main culprit for this is the presence of 10% DMSO (1.43 M!) in the reaction buffer: 
while MAGL has shown to work in these conditions with no negative effects, it is well-
known that DMSO can enchance heavily protein degradation (Tjernberg, Markova, 
Griffiths, & Hallén, 2006). However, a percentage of DMSO is required, in order to 
dissolve the largely hydrophobic compounds which are substrates for lipases. This 
dilemma found a possible solution when prof. Branchini’s group published the 
characterisation of PLG2, a Ppy/Lit chimeric luciferase which showed exceptional 
resistance to denaturing conditions (Branchini, Southworth, et al., 2015) and has then 
used for an extremely sensitive ATP assay in cells (Branchini & Southworth, 2017): the 
work in collaboration with his group then began. 
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4.2 Results and discussion 
4.2.1 Synthesis of the substrate 
The substrate arachidonoyl luciferin (ArLuc) was synthesized following an adaptation 
of the procedure for the synthesis of bioluminescent substrates for the analysis of 
hydrolytic enzymes by Toya and colleagues (Toya et al., 1992). Since this procedure 
does not involve luciferin as a reagent, it provides the important advantage of not 
having to protect and then de-protect the carboxyl free group of luciferin. The modified 
procedure included the use of DCC and DMAP for the direct coupling of arachidonic 
acid and the luciferin precursor 6-Hydroxy-2-cyanobenzothiazol. This first reaction 
produced a nitrile compound, which then readily reacted with D-cysteine hydrochloride, 
obtaining the desidered D-luciferin ester, with an overall yield of  29.4%. 
Unambiguous assignments of protons were recognized by 1D NMR spectra, as well as 
2D NMR homocorrelation (COSY), which were employed for complete structural 
assignments. The purity of the compound measured with NMR was greater than 98%. 
 
Figure 16. The luminogenic substrate ArLuc, with the carbon atoms mapped. 
The 1H-NMR spectra are reported in the Appendix, the assignements are (fig. 16): 0.91 
(3H, t, J=7.6, 20¢"-CH3), 1.28-1.40 (6H, m, 17¢”-19¢”-CH2), 1.87 (2H, tt, J=7.0, 7.6, 
3¢”-CH2), 2.07 (2H, dt, J=7.6, 7.6, 16¢”-CH2), 2.22 (2H, dt,  J=7.0, 7.4, 4¢”-CH2), 
Figure 15. Schematic procedure for the synthesis of ArLuc. R=Arachidonic acid 
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2.48 (2H, t, J=7.0, 2¢”-CH2), 2.82-2.88 (6H, m, 7¢”- 10¢”- and 13¢”-CH2), 3.80-3.87 
(2H, m, 3-CH2), 5.33-5.46 (9H, m, 5¢”- 6¢”- 8¢”- 9¢”- 11¢”- 12¢”- 14¢”- and 15¢”-
CH, 4-CH), 7.29 (1H, dd, J=8.9, 2.3, 5¢’-CH), 7.73 (d, J=2.3, 7¢’-CH), 8.16 (d, J=8.9, 
4¢’-CH), 10.16 (1H, bs, COOH). 
4.2.2 PLG2 recombinant expression 
E. coli cells (JM109) were transformed with the plasmid containing PLG2 cDNA, 
kindly provided by prof. Branchini’s lab. Transformation was tested using LB agar + 
ampicillin (LB+Amp) plates. The cells transformed with the vector were plated with no 
dilution, and at 1:10 and 1:100 dilution (in SOC medium). 
Three colonies were picked from the 1:10 plate, and used to inoculate three 5 mL tubes 
with 5 mL LB+Amp. These tubes were then used to inoculate three flasks with 245 mL 
LB+Amp liquid medium; these cultures were then left in incubation shaking at 37 °C 
300 rpm, while monitoring the OD at 600 nm.  
Figure 17. Bacterial plates for PLG2 transformation. JM109 cells were plated on LB-Amp agar after  being 
transformed with the pQE-30 vector, including the PLG2 gene. The cells were plated without being diluted (“N.D.”), 
or after being diluted ten times (“1:10”) or a hundred times (“1:100”). Non-transformed cells were also plated, as a 
negative transformation control (C-).  
The 250 mL liquid cultures 
reached an OD of ~0.56 in less 
than four hours from incubation, 
which gave the typical exponential 
growth curve (fig. 17). At that 
point the cultures were induced 
through the addition of IPTG 0.1 
mM (final) and transferred at 24 
°C, to allow a relatively low-
Figure 18. Bacterial growth curve for PLG2 expression. 
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temperature expression, in order to avoid protein precipitation. The cultures were left to 
express the protein o/n, shaking at 300 rpm. The following day, the cells were harvested 
frozen at -80 °C, in order for the protein to be purified later. The cells were then lysed 
and the protein purified on Ni-NTA agarose resin. A total of five purifications were 
carried out, their yields are detailed in Table 4. 
Table 4. PLG2 yields per purification run. 
Culture 
volume Total protein yield Yield per liter 
250 mL 8.8 mg 35 mg/l 
250 mL 5.5 mg 22 mg/l 
375 mL 4.1 mg 11 mg/l 
375 mL 10.8 mg 29 mg/l 
On average 24.3 mg/l 
 
4.2.3 PLG2 SDS-PAGE analysis 
 
Figure 19. SDS-PAGE gel for PLG2.  
On the left lane, the molecular ladder, with some molecular weights indicated in their kDa values. 
A: bacterial lysate 
B: purified PLG2 concentrate 
 
A SDS-PAGE experiment in denaturing conditions of the bacterial lysate and of the 
purified protein was set to visually check for the overexpression of the PLG2 luciferase. 
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The results are shown in fig. 18. The presence of PLG2 (~ 60 kDa) in the lane of the 
purified protein is evident, however an excess of protein concentrate in this sample 
(lane B contained 10 µl of concentrated protein, against 2 µl of the lysate in lane A) led 
to a gel overload.  This caused the apparition of some faint bands, belonging to 
unidentified trace proteins. 
4.2.4 PLG2 activity tests with DMSO 
The first trial to do was to assess PLG2 emission with different concentrations of 
DMSO in order to decide the concentration of DMSO in which MAGL substrates could 
be dissolved into. Five wells of 100 µl of buffer with 50 nM D-luciferin were measured 
in duplicate with 1%, 2%, 5% and 10% DMSO; five duplicate wells with no DMSO and 
ten blanks with 100 µl buffer and no luciferine nor DMSO were also measured as well, 
as positive and negative controls respectively. 
The resulting BL was measured each minute for five minutes. The results are reported 
in figure 20. 
A final concentration of 2.5% DMSO was chosen for further experiments, since it 
granted around 75% of the original luciferase activity and allowed a 5% DMSO 
concentration for dissolving MAGL substrates. 
Calibration curves with D-luciferin standards at different concentrations were then built 
for PLG2, to control the linearity of the response and look for the LOQ of the method. 
The tested LH2 concentrations were 0, 5, 12.5, 25, 50, 125, 250, 500, 1000 and 5000 
nM; all measurements were performed in triplicate.  
Figure 20. PLG2 luminescence emission in the presence of varying concentrations of DMSO. Each point is the result 
of a triplicate measurement, and results reported are RLU ± SD. 
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Figure 21. Linearity test for PLG2 on D-luciferin in the presence of 2.5% DMSO. The plotted values are the result of 
three wells each with the indicated LH2 concentration, ± SD. The luminescent signal proved to be linear in the 5 – 
500 nM range.  
The response proved to be linear up to a LH2 concentration of 500 nM; at 1 mM, the 
detector was saturated, and higher concentrations could not be determined, therefore a 
dynamic range of 0-500 nM was established. The LOD and LOQ for the assay were 
calculated according to these experiments: all blank values from the two independent 
experiments were averaged (n=6), and the resulting SD was used to calculate LOD and 
LOQ according to the formulas LOD=3σ/s and LOQ=10σ/s (Shrivastava & Gupta, 
2011), where “σ” is the average SD of the blanks and “s” is the slope of the calibration 
curve. The resulting values were LOD=90 pM and LOQ=300 pM. 
4.2.5 Assay development and validation 
Since BL had kept its promises of sensitivity, the next step was to test its feasibility for 
MAGL hydrolysis of ArLuc. All MAGL reactions were performed in-plate, then the 
PLG2 mix was automatically injected into the plate and the BL intensity measured 
exactly as reported above.  
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Figure 22. General concept of the assay. MAGL, ArLuc (and the inhibitor, if present) react inside the plate wells. To 
quantify the LH2 produced by MAGL hydrolysis, the luminometer injects the PLG2 assay mix, then waits for the 
non-quantitative flash burst to fade off, and records the luminescence emitted by the PLG2 luciferase. 
MAGL experiments were executed as follows. First, 10 µl of MAGL enzyme (25 ng) 
were pipetted at the bottom of the appropriate well, then 90 µl of the reaction mix, 
containing the appropriate amout of ArLuc dissolved in 5 µl DMSO (5% final, 2.5% 
once the PLG2 mix is added), were quickly added to the enzyme, and the plate was read 
immediately after. The reagent lines and injector were cleaned before and after use with 
70% ethanol. For this preliminary test, a solution of ArLuc 10 µM was prepared in 
DMSO; 45 µl of this solution were pipetted into a test tube and 765 µl of buffer were 
gradually added, vortexing the tube inbetween the buffer droplets in order to let the 
DMSO completely dissolve into the aqueous phase. A similar solution was prepared 
with no MAGL added, to obtain a signal coming exclusively from the spontaneous 
hydrolysis of ArLuc as well as possible LH2 impurities. A blank solution was also 
prepared, mixing 15 µl DMSO with 275 µl buffer.  
90 µl of this solution were then quickly added to each well containing MAGL, for a 
Figure 23. D-luciferin calibration curve for PLG2 (left) (R2=1.) and tests for MAGL hydrolytic activity on ArLuc (right).  
 53 
final ArLuc concentration of 25 pmol/well, and the plate was read immediately. Each 
well was prepared and read in duplicate. The result were four data points from 0 to 9 
minutes, each taken 3 minutes after the previous one. A LH2 calibration curve were also 
prepared, at final concentrations of  0.1, 0.5, 5 and 50 pmol. The data obtained from the 
MAGL assay were correlated to pmols of LH2 according to this curve. MAGL 
hydrolyzed ArLuc to luciferin and arachidonic acid (fig. 23), yielding 0.66 pmol LH2 
after 9 minutes, about 2.6% of the total ArLuc. Kinetic constants in our conditions were 
then determined for MAGL with ArLuc as substrate. Experiments were set up in the 
same fashion as above and, after some preliminary tests to “fish” for a rough Km value 
(not shown), we set up an experiment with different ArLuc concentrations to determine 
the precise Km and Vmax values. The concentrations chosen were 0.5, 1, 5, 8, 10 and 20 
µM, therefore staying in Michaelis-Menten conditions (Bisswanger, 2014). After the 
resulting values were converted into LH2 pmoles in accordance with the calibration 
curves, the data points were regressed to a linear curve. The slope of each curve was 
converted into pmoles/min/mg produced by the enzyme, and the values between the 
various experiments were averaged and fit to a Michaelis-Menten equation, corrected 
for substrate inhibition (fig. 24). 
 
Figure 24. Kinetic profile for MAGL in the assay conditions. Every point is the average of three values ± SD. The  
curve model is that of the Michaelis-Menten equation corrected for substrate inhibition: 
Y=Vmax*X/(Km + X*(1+X/Ki)) 
The final step was validation with a known MAGL inhibitor. In order to avoid false 
positive results, the behavior of PLG2 was tested in the presence of known MAGL 
inhibitors: MAFP, URB602 and JZL184. 
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The assay was carried out in the same conditions as negative controls for MAGL ones: 
the DMSO was used to dissolve the appropriate inhibitor concentration instead of 
ArLuc, and the wells contained 5 nM LH2 (final). Each data point was taken in 
triplicate. The concentrations used were the IC100 (defined as the IC50 literature value 
plus the SD, rounded up afterwards), and ten times this concentration. 
The results are shown in fig. 25. According to the results, it looked like relatively high 
concentrations of MAFP can have an effect on PLG2, while JZL184 has no relevant 
effect on PLG2. It is very interesting to note, though, that a carbamate inhibitor studied 
for hydrolases like URB602, inhibits a luciferase in a quantitative fashion. 
For our validation, we then chose JZL184, the well-known first specific inhibitor for 
MAGL with high potency (Long et al., 2009).  
The inhibitor was prepared in DMSO stocks forty times more concentrated than the 
final JZL184 concentration. The procedure followed was the same as for determination 
of kinetic constants, but this time the stock concentration of ArLuc was 320 µM 
(dilution factor 40, final concentration 8 µM), and the DMSO volume added to the mix 
was half as before for both inhibitor and substrate. Each point was assayed in triplicate, 
then the slopes were calculated as described above, but this time without converting 
Figure 25. PLG2 luminescence emission in the presence of different concentrations of various known MAGL 
inhibitors.The values reported are the average of three replicates. The asterisks indicate a significant deviance of 
the values from the 2.5% DMSO samples with no inhibitor added (yellow bar). ****: adjusted P value < 
0.0001; *: adjusted P value = 0.0403. 
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them to LH2 picomoles; instead, the slope of the line coming from the assay without 
inhibitor was taken as the 100% of the activity, while the slopes of the other curves 
were converted into various activity 
percentages referred to this curve. 
The final JZL184 concentrations used were 
0,10 nM, 100 nM, 500 nM, 1 µM, and 100 
µM. Results are reported in fig. 26; the found 
IC50 is about half that found in literature, but 
still stays in the order of magnitude of that 
reported previously, and at the lower range 
found in our previous publication (Lauria et 
al., 2015; Juha R. Savinainen, Yoshino, 
Minkkilä, Nevalainen, & Laitinen, 2010). 
4.3 Conclusion 
We synthesized ArLuc, an arachidonoyl luciferin compound specially designed for 
MAGL BL assays. MAGL was found to be able to hydrolyze it, producing free D-
luciferin which can be detected via BL methods. 
We also produced and purified recombinant PLG2 from bacterial cells, with good 
yields. It is interesting to note that, as reported in Table 4, while the difference in yield 
between the single purification runs is noteworthy, the average protein yield conforms 
precisely to the expected yield of ~24 mg/l of culture reported by Branchini’s group 
(Branchini & Southworth, 2017). The luciferase was then proved capable of catalyzing 
its peculiar reaction even in the presence of significant concentrations of DMSO, which 
confirms its exceptional stability and resistance to denaturing conditions. 
The method itself has, as promised, various pros and cons: it has an astonishing 
sensitivity, with a LOQ below the nanomolar range – namely, the assay is able to 
quantify LH2 from 60 attomoles per well. On the other hand, the very nature of 
luciferase emission in the fashion of “flashes” makes it necessary to prepare a different 
experiment for each time point, if continuous production of enzymatic action is to be 
monitored. Even adopting this way to circumvent this limitation, it won’t be as reliable 
as a continuous assay anyway, since each point actually is an experiment on its own. 
Also, this makes the assay less practical and cheap than a fluorometric one. A single-
Figure 26. Inhibition profile for JZL184 on MAGL 
in the assay conditions. Each point is the average of 
three different wells ± SD. 
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point measurement could solve these issues: while unsuitable to detect the initial rate of 
the enzyme activity (Bisswanger, 2014; Purich, 2010), the assay could be further 
tailored to use a sub-Vmax substrate concentration and to measure the hydrolase activity 
at its steady state in presence of absence of an inhibitor at a set time point (3-6 minutes 
seem suitable beginning points for assay design). This should be an easy adaptation 
assaying methodology, though, and it would solve most of the current disadvantages. 
BL assays, however, intrinsically offer multiple potential applications due to their 
selectivity and sensitivity. It was also interesting to find that a carbamate inhibitor such 
as URB602, which initially seemed extremely selective for MAGL, inhibits our 
luciferase. If nothing else, this reminds us of the unpredictability of unwanted 
interactions when developing a new drug, which should be investigated as carefully and 
early as possible. Regardless of assay developments, a luciferase which works in the 
presence of high quantities of DMSO is a precious addition to the enzymatic assay 
toolbox.  
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4.4 Experimental section 
Reagents and materials 
All reagents and solvents were bought from Sigma-Aldrich, unless specified. IPTG and 
ampicillin were bought as powders and dissolved into ddH2O to a 0.84 M (200 mg/mL) 
and a 100 mg/mL stock solution, respectively. The solutions were then filtered on a 0.2 
µm membrane, divided into 200 µl aliquots and stored at -20 °C. SOC medium for 
transformation was bought from Thermo Fisher (Waltham, MA, USA). All other 
buffers were made in-house according to the following recipes; these buffers should be 
stored at 4 °C and are viable for one week, unless specified. All plasticware used to 
work with bacteria was sterile, the culture mediums were sterilized using the autoclave, 
while the buffers were filtered on a 0.2 µm membrane. 
LB (LB-Lennox) culture medium: 10 g/l tryptone, 5 g/l yeast extract, 5 g/l NaCl. Bring 
to desired volume with ddH2O. When needed, ampicillin 100 µg/mL was added right 
before use, to minimize degradation. 
LB agar: 15 g/l agar, 10 g/l tryptone, 5 g/l yeast extract, 5 g/l NaCl. Bring to desired 
volume with ddH2O. When needed, ampicillin 100 µg/mL was added right before 
preparing the plates, to minimize thermal degradation. 
PCB buffer: 50 mM Tris, 150 mM NaCl, 1 mM DTT, 1 mM EDTA. Adjust to pH 7 
with HCl. 
PBS buffer: the buffer is commonly prepared as a 10x solution with 400 mM NaCl, 27 
mM KCl, 100 mM Na2HPO4, 1.8 mM KH2PO4 in ddH2O (pH 7.3), then filtrated on 0.2 
µm membranes and stored at RT. The solution is viable for a long time (about 6 
months). When PBS buffer is needed, the above 10x solution is diluted 1:10 with 
ddH2O; the PBS buffer is then normally stored at 4 °C and viable for 1 week. 
Four 10 mL elution solutions were prepared prior to the purification step dissolving 
imidazole in PBS at the final concentrations of 50 mM, 100 mM, 250 mM and 500 mM. 
These solutions were then kept in cold room at 4 °C. 
TE buffer: 10 mM Tris, 1 mM EDTA. Bring to pH 8 with HCl. 
Tris-HCL buffer: 50 mM Tris, 1 mM EDTA. Bring to pH 8 with HCl. 
PLG2 assay mix for LH2 determination: 0.8 mM ATP, 10 mM MgSO4 in 50 mM Tris-
HCl buffer. 
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Lysozyme (from egg white) solution is prepared by dissolving 10 mg/mL lysozyme in 
PBS and stored at 4 °C until use. RnaseA (from bovine pancreas) solution  was prepared 
dissolving 10 mg/mL RNaseA in 10 mM Tris buffer, pH 7.5, containing 15 mM NaCl. 
DNaseI solution is 5 mg/mL DNaseI (from bovine pancreas) in 10 mM Tris buffer, pH 
7.5 containing glycerol (1:1, v/v), 50 mM NaCl, 10 mM MgCl2, and 1 mM DTT. 
Synthesis of the bioluminescent substrate 
To a stirred solution of arachidonic acid (0.18 mmol) in anhydrous CH2Cl2 (3 mL), 
under an argon athmosphere and cooled in an ice bath, was added DMAP (2 mg, 0.01 
mmol) and 6-Hydroxy-2-cyanobenzothiazol (30 mg, 0.18 mmol). DCC (72 mg, 0.35 
mmoli) was added to the reaction mixture at 0 °C, dropwise. Stirring was continued o/n 
at room temperature. Product formation was confirmed by TLC (silica gel, mobile 
phase 95% petroleum ether, 5% ethyl acetate). The CH2Cl2 solution was washed twice 
with saturated NaHCO3 (2.5 mL), dried on anhydrous Na2SO4 and concentrated to give 
the crude product. The resulting brown oil was filtrated on column chromatography on 
silica gel by the same mobile phase as TLC, 95% petroleum ether, 5% ethyl acetate. 
The column chromatography was followed via TLC in the same conditions, and gave a 
yield of 80 mg (0.17) of the nitrile product, a colorless oil. 
The nitrile and D-cysteine hydrochloride monohydrate (0.19 mmol) were dissolved in a 
mixed solvent of 1.5 mL MeOH and 400 µl CH2Cl2, in an argon atmosphere. 500 µl 
ddH2O and K2CO3 (0.19 mmol) were added, and the solution was kept stirring at RT for 
1 hour. Another TLC was performed, in the same conditions as above, to control the 
product formation. HCl 1M was added until the solution reached a 2-3 pH value. A few 
mL of the organic reagents were evaporated under vacuum using a rotary evaporator, 
then the precipitate was collected and washed with water, to give ArLuc as a white 
solid. The filtration gave 30 mg of ArLuc (MW=566.77 U), which structure and purity 
were confirmed by NMR analysis. 
Bacterial transformation 
The vector used for PLG2 recombinant expression was pQE-30 plasmid, containing the 
PLG2 cDNA sequence and His-tag. The vector samples were kindly provided by prof. 
Branchini’s lab. The vector was carried to Italy adsorbed on filter paper, and was 
desorbed as follows: the paper was cut 1-2 mm around the area where the plasmid had 
originally been spotted (and circled with a pencil), then the paper circle was put into a 
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1.5 mL Eppendorf tube with clean tweezers. 100 µl TE buffer were pipetted into the 
tube, then the tube was vortexed briefly and incubated at RT for 5 minutes. The tube 
was then vortexed briefly again and centrifuged at 500 x g for a few seconds. 1 µl of the 
DNA was used to quantify the cDNA plasmid at a NanoDrop™ 2000 Microvolume 
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA), using the DNA 
preset protocol (quantitation based on λ=260 nm, λ=280 nm, and A260/A280 nm ratio).  
The E. coli cells used for the transformation and expression were Single-Use Promega 
JM109 Competent Cells (Promega, Fitchburg, WI, USA). All steps involving the cells 
were performed wearing sterile gloves, and in proximity to a Bunsen burner with blue 
flame, to avoid bacterial or mold contamination. Two aliquots (50 µl each) of cells were 
taken out of the deep freezer (-80 °C), and left to thaw on ice. After thawing, 10 µl of 
the TE plasmid solution (final plasmid concentration 0.22 ng/µl) was added to one 
aliquot. The other aliquot was used as a negative control of the transformation, adding 
10 µl of ddH2O instead of the TE+vector solution. Both tubes were then left on ice for 
10 minutes. A heat shock procedure was now carried out: the cells were put into a water 
bath at 42 °C for 45 seconds, then quickly put on ice again for 2 minutes, being careful 
not to shake the tubes in order to avoid mechanical stress to the cells. 900 µl of SOC 
culture medium was added to each tube, which were then put at 37 °C, shaking at 300 
rpm, for 1 hour. Transformation was tested plating the cells on LB agar + ampicillin 
100 µg/mL (LB+Amp) plates: the cells were first diluted 1:10 and 1:100 in fresh SOC 
medium, then 100 µl from each dilution was plated on an LB+Amp agar plate and put 
into an incubator set at 37 °C, o/n. 
PLG2 expression in liquid bacterial cultures 
The typical culture setup was of three 500 mL sterile flasks, with 245 mL LB culture 
medium each, which was poured under a laminar flow hood. During all the subsequent 
steps, the flasks were open in the proximity of a Bunsen burner lit on blue flame, to 
avoid external contamination. 
Three 5 mL “snap-cap” tubes with 5 mL LB+Amp were inoculated with three colonies 
picked from the 1:10 plate, using a sterile microbiology inoculation loop. The tubes 
were left at 37°C, shaking at 300 rpm o/n, along with an uninoculated tube with 5 mL 
LB+Amp as a control for contaminations. 
 60 
After 16h of growth, the three inoculated tubes were poured into one of the three 500 
mL flasks each (final volume 250 mL); these cultures were then left on incubation 
shaking at 37 °C 300 rpm, while monitoring the bacterial growth through the 
measurement of the cultures OD. 1 mL of culture into a disposable plastic cuvette. 
Meanwhile, the IPTG stock solution was diluted to a 0.1 mM working solution with 
sterile ddH2O water. 
At that point the cultures were added with 250 µl IPTG 100 mM, for a final 
concentration of 0.1 mM and transferred outside the incubator at controlled temperature 
of 24 °C, still shaking at 300 rpm, o/n. The following day, the cultures were evenly 
poured into two  centrifuge bottles, dividing them into two ~325 mL aliquots, and the 
cells were harvested through 10 min ultracentrifugation at 5000 x g, with the rotor 
bucket at 4 °C. The supernatant was discarded and the two aliquots of cells deep-frozen 
at -80 °C, in order for the protein to be purified at a later time. 
PLG2 protein purification  
During purification, all solutions were kept on ice and all centrifugation steps were 
performed with the rotor bucket set at a temperature of 4 °C. Resuspension buffer was 
prepared immediately prior to the purification, adding imidazole 5 mM and 38 µl of a 
PMSF solution (2.5 mg of PMSF dissolved into 100 µl ethanol 95%, prepared right 
before use) to 38 mL PBS buffer. Each bacterial pellet was thawed on ice and 
resuspended in the 38 mL of resuspension buffer (10% volume of culture) using a 
pipette, being careful to avoid foaming or bubbling. 3.8 mL of a lysozyme 10 mg/mL 
solution were added, then the cells were left on ice for 20 minutes. The cell lysis was 
then completed with sonication, carefully keeping the cells on ice and applying 3 bursts 
of 10 seconds each. The sonicator used was a SONOPULS HD2070 (BANDELIN, 
Berlin, Germany), at ~50% power (~35W). 38 µl of the DNase and RNase solutions 
were added to the lysate, and it was left on ice for 5 minutes. After a last addition of 1% 
(v/v) Triton X-100, the lysate was left on ice for 5 more minutes. The lysate was now 
centrifuged at 20.000 x g, for 45 minutes, then kept on ice. 
For affinity chromatography purification of the protein, 0.5 mL of Ni-NTA agarose 
slurry (Thermo Fisher) were used. The slurry was pipetted into a 50 mL tube, 
centrifuged at 500 x g for 5 minutes, and the supernatant was removed with the aid of a 
micropipette. The Ni-NTA agarose was washed with 20 mL of PBS, then it was 
centrifuged at 500 x g for 5 minutes, and the buffer discarded. This was repeated for 
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four more times in order to completely remove the storing ethanol from it. The lysate 
was now added to the slurry and incubated for 120 minutes in a cold room at 4 °C, 
shaking gently in order to allow PLG2 binding to the resin. 
After the binding, the resin was centrifuged at 500 x g, for five minutes and the 
supernatant removed and stored at 4 °C, in case of poor binding. The resin was washed 
with 5 mL ice cold PBS + 20 mM imidazole for four times, each time centrifuging it at 
500 x g for 2 minutes, then discarding the buffer. 
The resin was poured into a 10 mL Pierce™ Disposable Column (Thermo Fisher). The 
protein was eluted with PBS with increasing concentrations of imidazole. The imidazole 
concentrations used were 50 mM, 100 mM, 250 mM and 500 mM. For each elution step 
1 mL of elution solution was pipetted onto the resin and collected in an Eppendorf tube, 
except for the last one (500 mM) where 2 mL were used. The whole elution process was 
carried out in cold room at 4 °C. 
The fractions were then put on ice and quantified using the Bradford Protein Assay 
(Bio-Rad, Hercules, CA, USA), with BSA as a standard. The fractions with at least 1 
mg/mL were pooled. In order to remove the imidazole bound to PLG2, the protein 
concentrate was trasferred with a 10 mL disposable syringe into a 3-12 mL Slide-A-
Lyzer™ (Thermo Fisher) dialysis cassette with a 10.000 Da cutoff, and put into 1 L 
PCB buffer. The cassette was left to dialyze at 4°C for 24 hours with slow stirring. The 
buffer was changed every 3-4 hours (or o/n) for 5 times. 
The protein was then recovered from the cassette with a new 10 mL disposable syringe 
and quantified a second time with the Bradford assay. The protein concentrate was 
fractioned into 100-200 µl aliquots (the typical concentration of the protein concentrate 
was ~2 mg/mL), using 250 µl PCR tubes. The tubes were flash-frozen putting them into 
liquid nitrogen, and stored at -80 °C. 
 PLG2 SDS-PAGE 
SDS-PAGE experiments were performed using Mini-PROTEAN® II handcast systems 
(Bio-Rad, Hercules, CA, USA) kits for both equipment and reagents, unless specified. 
All SDS-PAGE gels were handcast into 50 mL Falcon tubes. Table 5 reports the 
quantities used for each gel casting. 
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Table 5. Recipes for SDS mini gels. The table reports the quantities needed to cast two complete gels. 
 Resolving gel Stacking gel 
dH2O 3.3 1.7 
30% Acrilamide/BIS  4.0 2.0 
1.5M Tris HCl ph 8.8 2.5 1.25 
10% SDS 100 µl 50 
10% APS 100 µl 50 
Temed 5 µl 2.5 
Totale volume 10 mL 5 mL 
Glass plates for the glass cassette sandwich were checked for the absence of chips or 
dents and carefully cleaned with 95% ethanol and lint-free cloths prior to assembling 
the glass cassette sandwich. The stacking and resolving gel were prepared in two 
separate 50 mL Falcon tubes, mixing carefully all reagents except for 
Tetramethylethylenediamine (TEMED). Then the TEMED was added to the resolving 
gel solution, the tube was closed, the solution gently mixed by inverting the tube, and 
the gel was immediately poured into the glass chamber for casting. Ethanol was poured 
on top of the separating gel solution during the polymerization process. 
After about one hour, once the resolving gel polymerized completely, the overlay 
ethanol was poured off, the resulting empty space was rinsed with ddH2O, and then 
carefully dried with lint-free tissue paper. TEMED was added to the stacking gel 
solution, then the solution was mixed as per above and the stacking gel solution was 
poured on top of the separating gel. The plastic comb was placed on top of the glass 
cassette, and the solution was left to polymerize for about another hour. The comb was 
then removed, and the gel was ready for use. More than one gel could be cast at the 
same time to be used within 24 hours: in this case, the comb was not removed, the 
whole glass cassette was enveloped with plastic paraffin film (Parafilm M – Bemis NA, 
Neenah, WI, USA) and stored at 4°C until use. 
The lysate samples were prepared adding 5 µl of the bacterial lysate to 1 µl 500 mM 
DTT, 2.5 µl Laemmli buffer 4x and 1.5 µl H2O. Purified protein samples were prepared 
adding 10 µl of the concentrated protein to 2 µl 500 mM DTT, and 4 µl Laemmli buffer. 
The tubes with the samples were put for 5 minutes into a Thermoblock set at 95°C, then 
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the gel was put into the electrophoretic cassette, the cassette was filled with running 
buffer, and the sample was carefully pipetted into the wells of the gel. The first and last 
well of the gel were loaded with 5 µl Precision Plus Protein Standards™ – All Blue. 
The gel was run at 200V for 40 minutes. 
The gel was coloured with Coomassie Blue through a microwave-assisted, water-based 
method: first, it was immersed in 100 mL dH2O, microwaved for 1 minute at 800W, 
then left on mild agitation for 2 minutes. The whole procedure was repeated two 
additional times. The staining was achieved immersing the gel in 100 mL SimplyBlue™ 
SafeStain (Thermo Fisher, Waltham, MA, USA), microwaving the gel at 800W for 30 
seconds, then leaving it on mild agitation for 15 minutes. The excess staining was 
removed by repeated washing steps with dH2O and leaving the gel in dH2O on mild 
agitation o/n. 
PLG2 DMSO trials 
For all experiments, the buffer used was Tris-HCl 50 mM pH 8.0, EDTA 1 mM. 
Before each experiment, the PLG2 fractions were unthawed at 37°C until only a small 
fraction of the solution (the size of about a small grain of rice) was still frozen, then left 
to unthaw at 4 °C. These unthawed fractions were used to prepare PLG2 assay mixes as 
needed. 
A PLG2 assay mix was prepared with Tris-HCl 50 mM pH 8.0 EDTA 1mM, NaATP 
0.8 mM, MgSO4 10 mM, PLG2 0.2 mg/mL. NaATP was prepared by dissolving a small 
amount (typically the amount picked by the tip of a small spatula) of powder in 1 mL 
Tris-HCl buffer, then 20 µl of the solution were added to 980 µl uf buffer, and the 
concentration of the solution was spectrophotometrically determined at λ=260 nm, 
applying Lambert-Beer’s law as ! = !!"#$$×200×1000 , where “A” is the recorded 
absorbance. Any leftover mix could be stored at 4 °C and used within 48 hours with no 
loss in performance. 
A concentrated solution of LH2 was prepared in a similar fashion to the NaATP one: the 
reading wavelength was λ=266 nm, and the formula applied ! = !!"##×200×1000, in 
accordance to LH2 different ε (Branchini & Southworth, 2017). 
The luminometer used was a GloMax®-Multi+ Microplate Multimode Reader 
(Promega, Fitchburg, WI, USA). All measurements were performed as follows: 100 µl 
 64 
of solution containing the amount of LH2 to be detected were pipetted into the wells of 
a white 96-well plate. The injection system of the instrument would then automatically 
inject 100 µl of PLG2 assay mix into the fisrt well to be analysed. After the injection, 
the luminometer had a lag time of 1 second, then integrated the luminescence signal for 
1 second. The luminometer would then pass to the following well to be analysed. 
Five wells of 100 µl buffer with 50 nM D-luciferin were measured in duplicate with 
1%, 2%, 5% and 10% DMSO; five duplicate wells with no DMSO and ten blanks with 
100 µl buffer and no luciferine nor DMSO were also measured as well, as positive and 
negative controls respectively. Each triplicate was prepared in a tube to ensure 
reproducibility. First, 12, 24, 60 or 120 µl DMSO, respectively, were pipetted into the 
tube; then the concentrated solution of LH2 was diluted to a 0.5 µM working solution, 
120 µl of this working solution were added to the DMSO – a blank was prepared, 
skipping this step. The appropriate amount of Tris-HCl buffer was then pipetted to bring 
the volume to 1.2 mL. 100 µl of this solution was pipetted into each of the ten plate 
wells. 
Linearity tests 
Calibration curves with D-luciferin standards at different concentrations were built, 
pipetting 20 µl DMSO in a test tube, then adding the appropriate amount of a LH2 
working solution (prepared as above, to a final concentration of 50 µM). The tested LH2 
concentrations (in-well) were 0, 5, 12.5, 25, 50, 125, 250, 500, 1000 and 5000 nM; all 
measurements were performed in triplicate. 
MAGL bioluminescent assays and kinetic tests 
Reagent solutions for MAGL experiments were prepared as follows. The quantities are 
intended for the typical assay, where 4 time points, each in triplicate, were read. 
The ArLuc substrate was dissolved in DMSO to a 1 mM stock solution; this stock 
solution was diluted with DMSO to a working solution 20x the final desired 
concentration in the assay (e.g. 100 µM for a 5 µM assay). A reagent solution was 
prepared using this working solution: first, 70 µl of the ArLuc working solution were 
pipetted into an Eppendorf tube (5% final, 2.5% once the PLG2 mix was added), then 
1190 µl of Tris-HCl buffer were added dropwise to the DMSO, vortexing the tube two 
or three times during the addition to avoid substrate precipitation. Reagent solutions for 
the negative controls were prepared as well, in the same fashion as above, but adding 
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1330 µl of Tris-HCl buffer instead. A blank solution and a LH2 calibration curve were 
also prepared: the blank solution was obtained mixing 15 µl DMSO with 275 µl buffer, 
while the calibration curve was obtained pipetting appropriate amounts of the 500 nM 
LH2 working solution into test tubes with 20 µl DMSO, then adding Tris-HCl ph8 
buffer with 1 mM EDTA to a final volume of 400 µl. The final LH2 concentrations were 
2, 5, 10, and 100 nM, DMSO 5%. The data obtained from the MAGL assay were 
correlated to pmols of LH2 according to this curve: in order to avoid confusion due to 
the MAGL reaction volume (100 µl) and the final volume with PLG2 assay mix added 
(200 µl), all LH2 quantities were expressed in terms of pmol/well, rather than molar 
ones. 
MAGL assays were set up as follows. The GloMax reagent lines and injector were 
cleaned before and after use with 70% ethanol, then abundantly rinsed with ddH2O 
water. 100 µl of the negative control reaction mix were pipetted in each appropriate 
well. hMAGL (Cayman Chemical, Ann Harbor, MI) was diluted to 250 ng/mL in 50 
mM Tris-HCl buffer pH 8, 1mM EDTA. 10 µl of the diluted MAGL enzyme (25 ng) 
were pipetted at the bottom of the appropriate well, then 90 µl of the reaction mix were 
quickly added to the enzyme, and the plate was read immediately after as per above. 
The result were four data points from 0 to 9 minutes, each taken 3 minutes after the 
previous one. 
The kinetic values were determined for MAGL with ArLuc as substrate. Experiments 
were set up in the same fashion as the ones above. This time, six reagent solutions were 
prepared, for ArLuc in-well final concentrations of 0.5, 1, 5, 8, 10 and 20 µM. The 
experiment was performed independently for two times, each time in duplicate or 
triplicate. The signal coming from negative control solutions was subtracted to that of 
the corresponding concentration and time point, in order to consider only the signal due 
to enzymatic hydrolysis. After the resulting values were converted into LH2 pmoles in 
accordance with the calibration curves, the data points were regressed to a linear curve. 
The slope of each curve was converted into pmoles/min/mg produced by the enzyme 
according to the formula 
!"#$!"#!" = !"!!!!"#$%!!"#$%!"! "#$ . The values between the various 
experiments were averaged and fit to a Michaelis-Menten equation, corrected for 
substrate inhibition, in accordance to the highest r2 value (best-fit). All calculations 
were performed with the Prism 6 software (GraphPad Software, La Jolla, CA, USA). 
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PLG2 inhibition   
Prior to the validation, the potential PLG2 inhibition by known MAGL inhibitors was 
determined. 
First, stock solutions were prepared for JZL184, URB602 and MAFP (Sigma-Aldrich): 
MAFP ethanol solution was diluted in DMSO to a 600 µM inhibitor solution, while 
JZL184 and URB602 powders were dissolved in DMSO to 280 µM and 10mM inhibitor 
solutions, respectively. Each inhibitor solution was then further diluted 1:10.  
Six reagent solutions were prepared, two for each inhibitor solution (diluted or not). 10 
µl DMSO and 10 µl inhibitor solution were slowly added with a 4 µM LH2 working 
solution, so that the final concentration would be 100 nM (50 nM after PLG2 addition). 
Tris-HCl pH8 50 mM, 1 mM EDTA was added dropwise to a final volume of 400 µl, 
vortexing every 3 drops added to avoid substrate or inhibitor precipitation. 100 µl of 
each solution were added to the micro plate wells, and the luminescence analysis was 
performed as described above. 
MAGL assay validation 
Five JZL184 working solutions were prepared. 
Table 6. Concentration of JZL184 working solutions and corresponding concentration on MAGL. 
JZL184 working solution 
concentration 
JZL184 concentration in-
well 
4 mM 100 µM 
40 µM 1 µM 
20 µM 500 nM 
4 µM 100 nM 
400 nM 10 nM 
0  0 (100%  MAGL activity) 
Validation solutions were prepared pipetting 35 µl JZL working solution into an 
Eppendorf tube (JZL184 concentrations are reported in Table 6). 1190 µl Tris-HCl pH 
8, 50 mM, 1 mM EDTA buffer were carefully added dropwise, vortexing after every 3 
drops to avoid inhibitor precipitation. 140 µl diluted MAGL solution (25 ng/well) were 
added, and the tubes were left to incubate at RT for 30 minutes. A blank solution, 
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consisting of 20 µl 380 Tris-Hcl buffer, was also prepared, as well as a negative control 
without MAGL (35 µl DMSO, 1330 µl buffer). 
10 µl DMSO with ArLuc 320 µM (in-well concentration 8 µM) were pipetted, and 90 µl  
of the validation and negative control solutions were pipetted onto it, then the 
luminescent analysis quickly began. The outptu consisted of a blank value in triplicate 
and four time points for every other solution, all taken at 3 minutes of distance (0, 3, 6 
and 9 minutes) in triplicate. 
The blank and negative control values were subtracted from all other RLU values. The 
resulting points were averaged and regressed to a linear curve (r2 ≥ 0.8348for every 
curve). The slopes were normalized, then that of the curve coming from the 0 µM 
JZL184 wells was taken as the 100% value, and the others were related to this one. The 
IC50 was calculated with Prism 6 (GraphPad software) using a log (inhibitor) vs. 
response – Variable slope (four parameters) function. 
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5. BACTERIAL RECOMBINANT EXPRESSION OF 
ABHD6 AND ABHD12 
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5.1 Introduction 
Most of the knowledge we have on the two hydrolases ABHD6 and ABHD12 comes 
from studies conducted on animal models or transiently transfected cell lines 
(Blankman et al., 2013, 2007; Fiskerstrand et al., 2010; Marrs et al., 2010; Muccioli et 
al., 2007; Parkkari et al., 2014; J. R. Savinainen et al., 2012). In particular, the ABHD6 
and ABHD12 recombinant expression was obtained through transient trasfection in 
HEK-293 and COS-7 cells (Blankman et al., 2007; Navia-Paldanius et al., 2012); while 
the use of these cell lines in research is well-established since the ‘70s and ‘80s 
respectively, and the techniques developed for these characterizations are indeed 
ingenious and trustworthy, they do not allow an intrinsic protein characterization nor, 
more importantly, provide enough pure protein for crystallographic studies with relative 
ease. 
Moreover, when working with whole cells or cell lysates, even the best experimental 
setup cannot attribute the observed activity exclusively to the overexpressed enzyme, 
due to the very nature of cell assays. 
The assays reported by the Cravatt group (Blankman et al., 2007) are based on an LC-
MS technique: the only screening assay published for these two hydrolases involves a 
sequence of four enzymatic reactions (Juha R. Savinainen et al., 2016a). After the 
hydrolysis of the substrate (a 1-AG) by the ABHD, the resulting glycerol is 
phosphorylated using ATP by a glycerol kinase, giving glycerol-1-phosphate which, in 
the presence of oxygen, is oxidated by a glucose phosphate oxydase to 
dihydroxyacetone phosphate, while the oxygen is reduced to hydrogen peroxide. 
Horseradish peroxidase catalyzes the last step, using H2O2 to convert the proprietary 
reagent Ampliflu™ Red into resorufin, which is finally fluorometrically detected.  
 
Figure 27. Reaction scheme of the assay for 
ABHD6 and ABHD12 proposed by Juha 
Savinainen and colleagues (Savinainen et al., 
2016). 
The scheme gives a good impression of how 
the misquantification occurring during a 
single step may compromise the outcome of 
the whole assay. 
Image made on the footprint of the authors’ 
one. 
 
This assay is tailored to work on 
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96-well plates and can screen up to 40 inhibitors for each plate: this makes it 
undoubtedly suitable for HTS. However, it still raises some perplexities. The need for 
four coupled enzymatic reaction steps means that the chances of an incorrect output due 
to an undetected activity loss of a stored enzyme aliquot are four times more likely than 
those of a single-step enzyme assay. A big plus of the assay is that it involves native 
substrates as the 1-AGs (although for ABHD12 the “native” characteristic of 1-AGs is 
debatable, see 1.1.3): nonetheless, this necessarily involves glycerol as a substrate 
which, as the same authors point out, puts the assay at risk of contaminations from 
residues of glycerol-containing detergents, if these are used for laboratory glassware 
and plastic reservoirs. Last but not least, the assay remains dependent on hABHD6-
HEK cell lysates, carrying over the uncertainty described above. 
A more convenient way to explore the properties of ABHD6 and ABHD12 could be the 
recombinant expression in bacterial hosts, namely the widespread E.coli BL21 strains: 
bacterial recombinant expression is generally viewed as the easiest, fastest, most 
convenient and economically efficient way to produce active proteins for a variety of 
purposes, including structural biology applications and enzymes for biochemical assays. 
The problem is posed by membrane proteins, which are difficult to produce for E.coli 
since the organism doesn’t have a dedicated machinery for the membrane insertion of 
the newly produced protein (Bernaudat et al., 2011; Chen, 2012). However, there are 
many reported cases of successful recombinant membrane protein expression in E.coli, 
to the point that the bacterium was found to be better than other, more promising, 
bacterial hosts such as Lactococcus lactis for the production of integral membrane 
proteins (Surade et al., 2006). 
As a first step for the development of in vitro assays for the determination of ABHD6 
and ABHD12 properties and inhibitor screening, we attempted the production of these 
two human membrane proteins in a E. coli BL21 strain. It should be noted that 
ABHD12 is a glycosylated protein, and this glycosylation cannot be achieved by 
unmodified E. coli cells. 
The main problem that can turn up during heterologous protein expression in E.coli (be 
them membrane proteins or not) is the storing of the recombinant protein in inclusion 
bodies (IBs) by the host organism. IBs are functional, non-toxic amyloids occurring in 
bacteria during the production of heterologous proteins, usually found in the 50-800 nm 
size scale (Rinas et al., 2017); they are the result of the overexpression of an insoluble 
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protein (Jonasson, Liljeqvist, Nygren, Stahl, & Ståhl, 2002), and can be considered a 
bacterial stress response to the forced overproduction of proteins (Rinas et al., 2017). 
IBs have traditionally been regarded as an inevitable drawback of bacterial recombinant 
production, because the protein they contain is mostly inactive due to incorrect or 
partial folding; while this view is recently being put into discussion by the consideration 
that they actually can be a valuable source of protein which can be recovered and 
correctly folded, we still wanted to avoid their formation as much as possible during 
these initial steps (García-Fruitós et al., 2012; Ramón, Señorale-Pose, & Marín, 2014; 
Rinas et al., 2017). 
A simple, classical way to prevent the accumulation of misfolded, insoluble protein 
within IBs is the avoidance of excessive protein production following the induction 
(Jonasson et al., 2002): our attempt was to use mild expression conditions, achieved 
using a medium culture such as lysogeny broth (LB), running the expression at sub-
optimal temperature and using a moderate concentration of inducer instead of the 
recommended one. These adjustments were meant to avoid excessive stress to the 
bacteria, which is increased when producing non-bacterial transmembrane proteins with 
respect to bacterial ones and can lead to stopped growth (Xu & Link, 2009), and an 
“overcrowded” intracellular milieu, which is more likely to produce amyloid aggregates 
(Magno, Caflisch, & Pellarin, 2010). 
5.2 Results and discussion 
5.2.1 ABHD6 and ABHD12 recombinant expression 
We decided to use a bacterial plasmid with an His-tag (6 His residues) at the protein N-
terminus, pPB-N-His; this was chosen both for future affinity chromatography 
purification and for antibody recognition.  
pPB-N-His plasmids including inserts for human ABHD6 and ABHD12 cDNAs were 
purchased ready from abm (Applied Biological Materials, Vancouver, Canada).  
Promega BL21(DE3)pLysS cells were transformed through a heat shock procedure, 
then transformation was checked using LB agar + kanamicin (LB+Kan) plates: the cells 
transformed with the vector were plated undiluted, at 1:10 and 1:100 dilution, in SOC 
medium as well. The plates were then left to grow o/n at 37 °C: plates where cells were 
plated after dilution showed no sign of growth, indicating a low transformation 
efficiency, but undiluted plates were spotted with colonies (fig. 28).  
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Figure 28. Plates with BL21(DE3)pLysS cells after transformation with ABHD6 (left) and ABHD12 (center) 
plasmids on LB-Kan agar. The negative control plate (right) was streaked with cells which were not transformed with 
the plasmid, but with ddH2O instead. 
 
The first trials were aimed at finding the optimal time after induction to harvest the 
protein. Five time points were chosen: 2, 4, 6, 16 and 24 expression hours. These were 
obtained in two runs, where six small cultures were prepared for each protein: the first 
experiment trialled the 2, 4 and 6 hours time points, while the second one tested the 6, 
16, and 24 hours ones. The 6-hours cultures were used as reference between the two 
experiments for the activity tests. Only three of the cultures were induced; each time an 
induced culture was harvested, an uninduced one was collected as well. Hydrolytic 
activity from these cells would serve as a baseline control for fluorometric activity 
assays (5.2.4). 
Colonies from both plates were picked, and used to inoculate three “snap-cap” tubes 
with 10 mL LB+Kan each, along with a third, uninoculated tube, which served as a 
contamination control. After 16h of growth, the inoculated tubes showed distinct 
turbidness, while the uninoculated one was clear. The three tubes were then used to 
inoculate six flasks, each with 45 mL LB+Kan liquid medium; these cultures were then 
left in incubation shaking at 37°C 300 rpm, while monitoring the OD at 600 nm. The 50 
mL liquid cultures reached an OD of ~0.8 in around four hours from inoculation. At that 
point, the cultures were induced with IPTG 0.1 mM (final) and transferred at 24 °C, still 
shaking at 300 rpm, and left expressing the protein o/n. The following day, the cells 
were harvested through 10 min centrifugation at 5000 x g. The supernatant was 
discarded and the two aliquots of cells frozen at -80 °C, in order for the hydrolase 
activity test to be performed at a convenient time. 
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The membranes were then resuspended in 600 µl ABHD buffer, then the fluorescence 
analysis immediately began (5.2.4). The remaining membranes were put at 4 °C, to be 
used in SDS-PAGE (5.2.2) and immunoblotting (5.2.3) experiments. 
5.2.2 Protein SDS-PAGE 
A SDS-PAGE experiment in denaturing conditions of the bacterial lysates was set to 
visually check for the overexpression (or an expression at all) of ABHD proteins.  
The results are reported in fig. 29, and do not show overexpression of any protein. 
 
Figure 29. SDS-PAGE results for ABHD6 (top) and ABHD12 (bottom). The first and last column are loaded with 
the Precision Plus Protein™ Standards Dual Color: the numerals indicate the molecular weight, expressed in 
kilodaltons, of the corresponding molecular standard. 
The other lanes were loaded with lysate samples harvested after different amounts of hours past the induction with 
IPTG. The numerals on top of the lanes indicate the amount of hours; a “plus” symbol means that the culture was 
actually induced, while a “minus” that the cells were not induced, but harvested at the same time (negative control). 
None of the samples shows a clear overexpression of the proteins. This could be due to the conditions of the 
expression, which were not geared towards a heavy protein overexpression, both in terms of culture medium and 
temperature. 
5.2.3 ABHD6 and ABHD12 immunoanalysis 
In order to assess the presence of the two recombinant proteins, a western blot analysis 
using anti-His tag antibodies was performed. The blotting results are reported in fig. 30, 
and confirm the presence of two His-tagged proteins at the expected molecular weights. 
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Figure 30. Western blot results for ABHD6 (top) and ABHD12 (bottom). The first and last column are loaded with 
the Precision Plus Protein™ Standards Dual Color: the numerals indicate the molecular weight, expressed in 
kilodaltons, of the corresponding molecular standard. 
The other lanes were loaded with lysate samples harvested after different amounts of hours past the induction with 
IPTG. The numerals on top of the lanes indicate the amount of hours; a “plus” symbol means that the culture was 
actually induced, while a “minus” that the cells were not induced, but harvested at the same time (negative control). 
The immunoblotting shows evident bands at the expected molecular weight for both proteins, which are 37 kDa for 
ABHD6 and 45 kDa for ABHD12. At this resolution, the lack of ABHD12 glycosylation is not appreciable.  
 
5.2.4 ABHD6 and ABHD12 membrane activity assay 
For the activity assay, we chose to use a simple variation of our fluorometry assay 
(Section 3), employing 7-Hydroxyresorufinyl laurate (1d) as the substrate. The decision 
was taken because it seemed a good compromise choice for the substrate preferences of 
the two enzymes (Navia-Paldanius et al., 2012), and also because we expected high 
base activity from other bacterial hydrolases, and did not want to saturate the RFU 
counter of the instrument. The results of the assay are reported in fig. 31.  
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Figure 31. Fluorescence time course for ABHD6 (top) and ABHD12 (bottom). The time courses reported refer to the 
hydrolytic activity of membrane suspension on 7-hydroxyresorufinyl laurate (compound 1d, 2.1.3), leading to lauric 
acid and 7-hydroxyresorufin. The membrane suspensions come from lysates harvested after 2, 4, 6, 16 and 24 hours, 
from left to right and top to bottom. 
The signals reported come from 7-hydroxylaurylresorufin with no membranes added (triangles), membranes of non-
induced cells (empty squares) and membranes of induced cells (circles). 
 
5.3 Conclusion 
The preliminary results for the heterologous expression of ABHD6 and ABHD12 in 
engineered E. coli BL21 strains are extremely promising. Despite the intrinsic 
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difficulties of the expression of mammalian integral membrane proteins in bacterial 
hosts, both the immunoblotting tests and the activity assays in fluorometry suggest that 
the expression was successfully carried out, and at least a portion of the expressed 
protein is active. 
The experimental protocol has provided important indications on the optimal expression 
time: the cultures harvested six hours after the expression have provided the highest 
levels of enzymatic hydrolysis of the substrate for both ABHD6 and ABHD12 – 
actually, at the current point this seems the only viable time point for ABHD6. These 
are, of course, only preliminary data, providing plenty of fascinating future possibilities: 
the experimental protocol has shown the potential to express these two hydrolases in 
bacterial hosts, but at the moment this expression looks relatively limited in quantity, so 
the protocol itself should be tuned for higher yields. Before this, a purification 
procedure should be established: it is imperative that the process is designed with the 
precise aim of maintaining the proteins in their active conformations, therefore mild 
detergents which use is specially established for this purpose is highly recommended. 
The His-tag at the N-ter of the two proteins should help in the purification process using 
the IMAC technique, providing this would not lower the yield in terms of active 
proteins, due to phenomena of denaturation. 
The activity assays show that a simple one-step analysis using a single fluorogenic 
probe can quantitate the activity of the ES ABHD hydrolases, as well as giving 
important clues that the proteins expressed are, at least in some percentages, active. 
Should the purification be achieved, the development of such a simple assay, taking 
advantage of the availability of isolated recombinant protein, should subsequentially 
achieved with relative ease. 
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5.4 Experimental section 
For general principles of working with bacteria, preparation of solutions, and buffer and 
culture medium recipes, refer to 4.4. 
Reagents and solutions 
Kanamicin was bought as a powder from Sigma, and dissolved into ddH2O to a 50 
mg/mL stock solution. The solution was then filtered on a 0.2 µm membrane, divided 
into 200 µl aliquots and stored at -20 °C. When needed, kanamicin 50 µg/mL was added 
to the culture mediums right before use (inoculation of the liquid culture or plate casting 
liquid), to minimize degradation. 
TGS buffer pH 8.3 was prepared as a 10x stock solution, dissolving 30.3g Tris base, 
144.0g glycine and 10.0g SDS in 1L dH2O. It was then filtered on a 0.2 µm membrane 
and stored at RT. Prior to use, it was diluted ten times to a working solution with dH2O, 
and stored (and used) at 4 °C. 
Towbin transfer buffer was prepared as a 10x stock solution, dissolving 30.3g Tris-Base 
144.15 g Glycine, 100mL. It was then filtered on a 0.2 µm membrane and stored at RT. 
Prior to use, it was diluted ten times to a working solution with dH2O. 
TBS buffer was prepared as a 20 mM Tris pH 7.6, 137 mM NaCl, solution in ddH2O, 
filtered as above and stored at RT in the dark. 
ABHD buffer was prepared according to the twin methods from Savinainen and 
colleagues (Juha R. Savinainen et al., 2016b): 100 mM Tris-HCl pH 7.4, 2 mM EDTA, 
10 mM MgCl2, and 200 mM NaCl, stored at 4 °C and brought to RT before use. 
Bacterial transformation 
pPB-N-His plasmids including inserts of human ABHD6 and ABHD12 cDNAs were 
purchased ready from abm (Applied Biological Materials, Vancouver, Canada). The 
cells used for the transformation and expression were BL21(DE3)pLysS cells 
(Promega). All steps involving the cells were performed wearing sterile gloves, and in 
proximity to a Bunsen burner with blue flame, to avoid bacterial or mold contamination. 
Three aliquots (50 µl each) of cells were taken out of the deep freezer (-80 °C), and left 
to thaw on ice. 0.5 µl (25 ng) of plasmid were pipetted onto each of them; one aliquot 
received the plasmid containing ABHD6, another one the plasmid containing ABHD12 
and the last one was pipetted with 0.5 µl of ddH2O, as a negative control. After a 10-
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minute incubation on ice, the cells were put into a water bath at 42 °C for 45 seconds 
and then quickly put back on ice for 2 minutes. During this step, particular attention was 
paid not to shake the tubes in order to avoid mechanical stress to the cells. Then, 900 µl 
of SOC culture medium (Invitrogen) at room temperature were added to each tube. The 
tubes were then put at 37°C, shaking at 300 rpm, for 1 hour. Transformation was 
checked using LB agar + kanamicin 50 µg/mL (LB+Kan) plates: the cells transformed 
with the vector were plated undiluted, at 1:10 and 1:100 dilution, in SOC medium as 
well. The plates were then left to grow o/n at 37 °C. 
Bacterial liquid cultures 
Three colonies were picked from each plate, and used to inoculate three “snap-cap” 
tubes, filled with 15 mL LB + Kan each. The tubes were put in an incubator at 37°C, 
shaking at 300 rpm o/n, together with an uninoculated tube with 5 mL LB+Kan as a 
control for the likelihood of contaminations from unwanted microorganisms. After 16h 
of growth, the inoculated tubes showed distinct turbidness, while the uninoculated one 
was clear. The two inoculated tubes were then used to inoculate six flasks (one tube 
inoculated three flasks, 5 mL per flask,), each with 45 mL LB+Kan liquid medium 
(final volume 50 mL); these cultures were then put into the incubator, shaking at 37°C 
300 rpm, while monitoring the OD at 600 nm. Meanwhile, the IPTG stock solution was 
diluted to a 0.1 mM working solution with sterile ddH2O water. When the cultures 
reached an OD of ~0.8, they were induced with 50 µl IPTG 100 mM, for a final 
concentration of 0.1 mM, and transferred outside the incubator at controlled 
temperature of 24 °C, still shaking at 300 rpm, o/n. The following day, the cells were 
harvested through 10 min centrifugation at 5000 x g, with the rotor bucket at 4 °C. The 
supernatant was discarded and the two aliquots of cells deep-frozen at -80 °C, in order 
for the membranes to be tested at a later time. 
Bacterial membrane isolation 
During this step, all solutions were kept on ice and all centrifugation steps were 
performed with the rotor bucket set at a temperature of 4 °C. Each bacterial pellet was 
thawed on ice and resuspended in 5 mL of PBS buffer (10% volume of culture) using a 
pipette, being careful to avoid foaming or bubbling. 0.5 mL of a lysozyme 10 mg/mL 
solution were added, then the cells were left on ice for 20 minutes. The cell lysis was 
completed with sonication, carefully keeping the cells on ice and applying 3 bursts of 
10 seconds each. The sonicator used was a SONOPULS HD2070 (BANDELIN, Berlin, 
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Germany), at ~50% power (~35W). 5 µl of the DNase and RNase solutions were added 
to the lysate, and it was left on ice for 5 minutes. The lysate was now centrifuged at 
20.000 x g, for 45 minutes, then the supernatant was removed, the membranes briefly 
resuspended in ice-cold PBS and centrifuged again in the same conditions for 5 
minutes. The PBS was discarded. The membranes were then resuspended in 600 µl 
ABHD buffer, then the fluorescence analysis immediately began. The residual 
membranes (~60 µl) were put at 4°C, to be used in SDS-PAGE and immunoblotting 
experiments. 
ABHD6 and ABHD12 SDS-PAGE 
SDS-PAGE experiments procedures and gel recipes can be found at paragraph 4.4.  
The lysate samples were prepared adding 5 µl of the bacterial lysate to 1 µl 500 mM 
DTT, 2.5 µl Laemmli buffer 4x and 1.5 µl H2O, and the molecular ladder used was 5 µl 
Precision Plus Protein Standards™ – Dual Color (Bio-Rad). 
ABHD6 and ABHD12 immunoblotting 
10 µl of resuspended membranes from each culture were added with 3.5 µl 4x Laemmli 
Sample Buffer and 1.5 µl of 500 mM dithiothreitol as a reducing agent. The samples 
were denatured for 5 minutes into a Thermoblock at 95°C, then they were removed and 
immediately put on ice. The samples were briefly centrifuged at 500 x g in order to 
collect the whole sample at the bottom of the tube, then they were pipetted into the 
wells of an SDS-PAGE gel immersed in running buffer. The gel was ran for 35 minutes, 
200V. 
The gel was equilibrated in Towbin transfer buffer at RT for 10 minutes on mild 
agitation, along with 6 sheet of 0.8 mm filter paper. Meanwhile, the blotting membrane 
was cut from an Immobilon-P PVDF sheet (-Merck), and activated by immersing it in 
methanol for 30 seconds. The membrane was then washed (2-minutes immersion in 
dH2O) and equilibrated through immersion in Towbin buffer for 10 minutes, on mild 
agitation. 
After both the gel and the membrane were equilibrated, the proteins were transferred to 
the membrane through a “transfer sandwich”, stacking three sheets of filter paper, the 
gel, the PVDF membrane, and then three more sheets of filter paper on the transfer 
cassette. The components were stacked on top of the anode, and the cathode was put at 
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the top of the sandwich. The transferral system was Bio-Rad Trans-Blot Turbo, and the 
“Standard SD” protocol (30 minutes at 25V, 1.0 A) was used. 
Once the transfer was completed, the membrane was “blocked” from aspecific 
membrane binding of the antibody through immersion in a TBS 3% BSA solution and 
kept o/n at 4°C on mild agitation. 
The antibody (abcam Anti-6X His tag® antibody [HIS-1] (Alkaline Phosphatase)) was 
diluted 1:1000 (10 µl antibody in 10 mL TBS added with 1% BSA). The membrane was 
immersed in the antibody solution for 1 hour at room temperature, on mild shaking; the 
membrane was then removed from the antibody solution, and washed three times with 
TBS with 1% Tween 20 added, for 5 minutes each time. 
A Sigma SIGMA FAST™ BCIP/NBT tablet was dissolved in 10 mL dH2O to obtain the 
phosphatase substrate solution. The final step of the immunoblotting consisted in 
immersing the membrane for 10 minutes in this solution, then rinsing it with dH2O, and 
leaving the membrane to dry in the dark. 
ABHD6 and ABHD12 activity assay 
7-Hydroxyresorufinyl laurate powder (1d, 3.2.1) was dissolved in DMSO in a 1 mM 
stock solution, then the stock solution was diluted with DMSO to a 50 µM working 
solution. 
20 µl of this working solution were pipetted at the bottom of the wells of 96-well plate, 
then 180 µl of resuspendend membranes were quickly pipetted on top of each substrate-
containing DMSO drop, and the fluorescence analysis immediately began. 
The plates were read (λex=571 nm, λem=588 nm) every 3 minutes, for 90 minutes using a 
Jasco FP-8300 fluorometer (3.4). 
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6. GENERAL CONCLUSION  
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In the present work, we illustrate two photochemical approaches to HTS screening of 
compounds dedicated to the inhibition of the hydrolases which regulate the ES, and the 
first attempts at the development of a third one. 
The fine regulation of the EC signaling is a promising topic for the treatment of various 
kinds of diseases and pathological conditions, as well as the maintaining of a well-being 
state. The fluorometric technique is a well-established one, and our assay is a fast and 
efficient one for the discrimination of promising lead compounds. The bioluminescent 
assay can be considered a more complex but finer instrument, which can act as a 
building block in the development of more advanced ones, but that nonetheless 
demonstrates that this interesting technique can be applied to the study of lipases 
involving lipophylic substrates. The ES ABHDs are a novel topic which surely needs 
more addressing, and our studies move forward towards that direction, with the promise 
of simplifying the characterization of these proteins without interferences from other 
cellular lipases.  
The ES on its own is a system which still holds many discoveries to be done for the near 
future, and our efforts aim at providing tools which make this investigation more 
accessible and efficient. 
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APPENDIX: NMR SPECTRAL DATA 
 
Table 7. NMR assignments for resorufin compounds (3.2.1). 
 1a 1b 1c 1d 1e 1f 
 δ (H) δ (C) δ (H) δ (C) δ (H) δ (C) δ (H) δ (C) δ (H) δ (C) δ (H) δ (C) 
CH(1) 7.46 (d) 
9.8 
134.8 7.46 
9.9 
134.8 7.47 
9.8 
134.8 7.47 
9.8 
134.8 7.46 
9.8 
134.8 7.46 
9.8 
134.8 
CH(2) 6.89 (dd) 
9.8, 2.0 
135.2 6.89 
9.9, 2.1 
135.1 6.90 
9.8, 2.0 
135.1 6.90 
9.8, 2.0 
135.1 6.89 
9.8, 2.0 
135.1 6.90 
9.8, 2.0 
135.1 
C(3)  186.3  186.3  186.4  186.3  186.3  186.3 
CH(4) 6.36 (d) 
2.0 
107.2 6.36 
2.1 
107.2 6.37 
2.0 
107.2 6.37 
2.0 
107.2 6.36 
2.0 
107.2 6.36 
2.0 
107.2 
CH(6) 7.18 (d) 
2.4 
119.3 7.18 
2.4 
119.3 7.18 
2.4 
119.3 7.18 
2.4 
119.3 7.18 
2.4 
119.3 7.17 
2.4 
119.3 
C(7)  153.6  153.6  153.7  153.7  153.7  153.7 
CH(8) 7.15 (dd) 
8.6, 2.4 
109.7 
 
7.15 
8.6, 2.4 
109.7 
 
7.15 
8.6, 2.4 
109.7 
 
7.15 
8.6, 2.4 
109.7 
 
7.14 
8.6, 2.4 
109.7 
 
7.15 
8.6, 2.4 
109.7 
 
CH(9) 7.82 (d) 
8.6 
131.1 7.82 
8.6 
131.1 7.83 
8.6 
131.1 7.83 
8.6 
131.1 7.82 
8.6 
131.1 7.83 
8.6 
131.1 
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C(11)  148.2  148.2  148.2  148.2  148.2  148.2 
C(12)  149.3  149.3  149.3  149.3  149.3  149.3 
C(13)  144.3  144.3  144.4  144.4  144.4  144.4 
C(14)  131.1  131.1  131.1  131.1  131.2  131.1 
COO  171.2  171.2  171.4  171.4  171.4  171.4 
OCOCH2   2.62 
7.0 
36.2 2.63 (t) 
7.5 
34.4 2.63 
7.5 
34.4 2.63 
7.5 
34.4 2.63 
7.0 
34.4 
CO 
CH2CH2 
  1.84 
7.0, 7.4 
18.3 1.79 (tt) 
7.5, 7.5 
31.6 1.79 
7.5, 7.5 
24.8 1.79 
7.5, 7.5 
24.8 1.80 
7.0, 7.0 
24.8 
CH=CH           5.42-5.34  
(2H, m, 9!, 
10!) 
129.7 (9!),  
130.1 (10!) 
CH=CH-
CH2 
          2.08-2.02 
(4H, m, 8!, 
11!) 
27.2 (8!),  
27.2 (11!) 
CH2-FACa     1.27-
1.47 
(20 H, 
29.0, 
28.9, 
24.8, 
1.47-
1.24 
(16 H, 
22.7, 29.1, 
29.2, 29.3, 
29.4, 29.6, 
1.46-
1.25 
(32 H, 
22.7, 29.1, 
29.2, 29.4, 
29.4, 29.6, 
1.45-1.26 (20 
H, m, 17!) 
22.7 (17!), 29.0, 29.1, 
29.1, 29.3, 29.5, 29.7, 
29.8 (4!-7! and 12!-
 100 
m, 4!-7!) 22.6 m, 4!-
11!) 
31.9 (4!-11!) m, 4!-
19!) 
29.6, 29.7, 
29.7, 29.7, 
31.9 (4!-19!) 
15!), 31.9 (16!) 
CH3 2.38 21.2 1.09 
7.4 
13.6 0.93 
7.0 
14.1 0.94 
7.1 
14.1 0.90 (t) 
7.0 
14.1 0.94 14.1 
 
 
 1g 1h 1i 1j 1k 
 δ (H) δ (C) δ (H) δ (C) δ (H) δ (C) δ (H) δ (C) δ (H) δ (C) 
CH(1) 7.46 
9.8 
134.8 7.46 (d) 
9.8 
134.8 7.47 (d) 
9.8 
134.8 7.47 (d) 
9.8 
134.8 7.49 
9.8 
134.8 
CH(2) 6.89 
9.8, 2.0 
135.2 6.89 (dd) 
9.8, 2.0 
135.1 6.90 (dd) 
9.8, 2.0 
135.1 6.90 (dd) 
9.8, 2.0 
135.1 6.91 
9.8, 2.0 
135.2 
C(3) 6.36 
2.0 
186.3  186.3  186.3  186.3  186.3 
CH(4) 7.17 
2.4 
107.3 6.36 (d) 
2.0 
107.2 6.36 (d) 
2.0 
107.2 6.36 (d) 
2.0 
107.2 6.38 
2.0 
107.3 
 101 
CH(6)  119.3 7.16 (d) 
2.4 
119.3 7.16 (d) 
2.4 
119.4 7.16 (d) 
2.4 
119.4 7.32 
2.4 
119.5 
C(7) 7.14 
8.6, 2.4 
153.6  153.8  153.8  153.8  153.8 
CH(8) 7.82 
8.6 
109.7 7.14 (dd) 
8.6, 2.4 
109.7 
 
7.13 (dd) 
8.6, 2.4 
109.8 
 
7.13 (dd) 
8.6, 2.4 
109.7 
 
7.30 
8.6, 2.4 
109.9 
 
CH(9)  131.2 7.83 (d) 
8.6 
131.1 7.83 (d) 
8.6 
131.2 7.83 (d) 
8.6 
131.1 7.89 
8.6 
131.2 
C(11)  148.3  148.2  148.2  148.2  148.3 
C(12)  149.4  149.4  149.3  149.3  149.4 
C(13)   144.4  144.4  144.4  144.4  144.5 
C(14)  131.2  131.1  131.1  131.1  131.2 
COO 2.65 (t) 
7.0 
33.7 (2!)  174.5  174.1  174.2  164.4 
OCOCH(2,1)(CH2)n 1.88 (3!) 
7.0, 7.3 
24.6 (3!) 2.75 (tq) 
7.0, 7.0 
39.7 2.58 (dq) 
7.7, 7.0 
47.4 2.63 (tt) 
7.0, 7.0 
45.9   
OCOCH(2,1)(CH2)n 5.52-5.33  130.6,129.4,128.7, 1.84 (3!) 33.3 1.80 (dt) 31.6 1.83-1.74 32.4   
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(8H, m, 5!,6!,8!,9!, 
11!,12!, 14!,15!) 
128.5,128.4,128.0,
127.8,127.5 
(5!,6!,8!,9!, 11!,12!, 
14!,15!) 
7.0, 7.0 7.4, 7.0 (2H, m) 
1.67-1.59 
(2H, m) 
 
 
CH=CH 2.88-2.82 
(6H, m, 7!, 10!, 
13!) 
27.3 (7!, 10!, 13!)  -  -  -   
CH=CH-CH2 2.25 (4!, dt) 
7.0, 7.3 
1.39-1.28 (6 H, m, 
17!-19!) 
22.6 (19!), 29.3 
(17!), 31.6 (18!), 
26.5 (4!), 25.7 
(16!) 
 
 -  -  -   
CH2-FACa   1.64-1.58 
(2H, m) 
1.45-1.39 
(2H, m) 
29.4 
22.6 
1.74-1.62 
1.46-1.36 
(6H) 
29.6 
25.4 
22.6 
1.44-1.28 
(12H, m) 
32.1, 
31.7, 
29.7, 
29.2, 27.5 
22.6  
 
  
 103 
CH3 0.91 (t) 
7.6 
14.1 1.34 (d) 
7.2 
0.97 (t) 
7.0 
14.0 
16.9 
1.06 (t) 
7.4 
0.97 (t) 
7.0 
11.9 
14.0 
0.96 (t) 
7.0 
0.92 (t) 
7.0 
14.0 
14.1 
  
o-Har         8.24 (d) 7.7 130.4 
m-Har         7.58 (t) 7.7 128.8 
p-Har         7.72 (t) 7.7 134.2 
 
1H and 13C NMR spectra of 7-hydroxyresorufinyl-acetate (1a) 
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1H and 13C NMR spectra of 7-hydroxyresorufinyl-butyrate (1b) 
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1H and 13C NMR spectra of 7-hydroxyresorufinyl-octanoate (1c) 
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1H and 13C NMR spectra of 7-hydroxyresorufinyl-laurate (1d) 
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1H and 13C NMR spectra of 7-hydroxyresorufinyl-icosanoate(1e) 
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1H and 13C NMR spectra of 7-hydroxyresorufinyl-oleate (1f) 
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1H and 13C NMR spectra of 7-hydroxyresorufinyl-2-methylhexanoate (1h) 
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1H and 13C NMR spectra of 7-hydroxyresorufinyl-2-ethylhexanoate (1i) 
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1H and 13C NMR spectra of 7-hydroxyresorufinyl-2-butyloctanoate (ij) 
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H and 13C NMR spectra of 7-hydroxyresorufinyl-2-benzoate (1k) 
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1H and 13C NMR spectra of 7-hydroxyresorufinyl-arachidonate (7-HRA, 1g) 
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1H and COSY spectra of arachidonoyl luciferin (ArLuc) 
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